<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Chem Res</journal-id><journal-id journal-id-type="iso-abbrev">Med Chem Res</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Medicinal Chemistry Research</journal-title></journal-title-group><issn pub-type="ppub">1054-2523</issn><issn pub-type="epub">1554-8120</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11315725</article-id><article-id pub-id-type="pmcid-ver">PMC11315725.1</article-id><article-id pub-id-type="pmcaid">11315725</article-id><article-id pub-id-type="pmcaiid">11315725</article-id><article-id pub-id-type="pmid">39132259</article-id><article-id pub-id-type="doi">10.1007/s00044-024-03227-x</article-id><article-id pub-id-type="publisher-id">3227</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Development of semisynthetic saponin immunostimulants</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Bai</surname><given-names initials="D">Di</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hyunjung</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0285-2069</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="P">Pengfei</given-names></name><address><email>wangp@uab.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008s83205</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0634 4187</institution-id><institution>Department of Chemistry, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>Birmingham, AL AL35294 USA </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>5</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>33</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">468604</issue-id><fpage>1292</fpage><lpage>1306</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>11</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="44_2024_Article_3227.pdf"/><abstract id="Abs1"><p id="Par1">Many natural saponins demonstrate immunostimulatory adjuvant activities, but they also have some inherent drawbacks that limit their clinical use. To overcome these limitations, extensive structure-activity-relationship (SAR) studies have been conducted. The SAR studies of QS-21 and related saponins reveal that their respective fatty side chains are crucial for potentiating a strong cellular immune response. Replacing the hydrolytically unstable ester side chain in the C28 oligosaccharide domain with an amide side chain in the same domain or in the C3 branched trisaccharide domain is a viable approach for generating robust semisynthetic saponin immunostimulants. Given the striking resemblance of natural <italic toggle="yes">momordica</italic> saponins (MS) I and II to the deacylated <italic toggle="yes">Quillaja Saponaria</italic> (QS) saponins (e.g., QS-17, QS-18, and QS-21), incorporating an amide side chain into the more sustainable MS, instead of deacylated QS saponins, led to the discovery of MS-derived semisynthetic immunostimulatory adjuvants VSA-1 and VSA-2. This review focuses on the authors&#8217; previous work on SAR studies of QS and MS saponins.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Vaccine adjuvant</kwd><kwd>Immunostimulant</kwd><kwd>Saponin</kwd><kwd><italic toggle="yes">Momordica cochinchinensis</italic></kwd><kwd>VSA-1</kwd><kwd>VSA-2</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/</institution-id><institution>National Institute of Health</institution></institution-wrap></funding-source><award-id>GM120159</award-id><award-id>GM120159</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Pengfei</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Vaccine adjuvants are increasingly important to vaccine development owing to their ability to enhance and/or modulate antigen-specific immune responses. Currently, only a few immunostimulating organic compounds, in different formulations and combinations, have been approved by the FDA for human use. They are MPL (monophosphoryl lipid A), QS-21 (a saponin isolated from tree bark extract of <italic toggle="yes">Quillaja Saponaria</italic> Molina), and CpG ODNs (oligodeoxynucleotides of cytosine and guanine with phosphodiester backbone) [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. Among them, QS-21 is arguably the most potent immunostimulant, enhancing antigen-specific humoral and cellular immune responses. The combination of QS-21 with MPL in a liposomal formulation, known as AS01b developed by GlaxoSmithKline (GSK), was recently approved for human use in GSK&#8217;s shingles vaccine, <italic toggle="yes">Shingrix</italic>&#174;, and malaria vaccine, <italic toggle="yes">Mosquirix</italic>&#174; [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Most recently, Novavax&#8217;s COVID-19 vaccine, adjuvanted with Matrix-M<sup>TM</sup> (a QS-21-containing saponin mixture in nanoparticle form) [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>], was approved by the FDA in 2022. QS-21 in different formulations or combinations with other adjuvant(s) has also shown promise in many candidate vaccines, including those in recent clinical trials [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>] and preclinical studies [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par3">However, QS-21 has its own drawbacks. It is a mixture of natural saponins that contains at least two structural isomers: QS-21<sub>xyl</sub> and QS-21<sub>api</sub>. The only structural difference of these two isomers is that QS-21<sub>xyl</sub> has a terminal &#946;-D-xylopyranosyl unit at the C28 linear tetrasaccharide while QS-21<sub>api</sub> has a terminal &#946;-D-apiofuranosyl unit. These saponins are primarily isolated from the tree bark of <italic toggle="yes">Quillaja saponaria</italic> Molina (QS), which is native to Chile. Between 2009 and 2012, harvests of QS biomass increased from 5700 to 11,600 tons, representing an average annual growth of 19.4%. Overexploitation of QS trees has led to severe ecological damage, consequently, strict environmental regulations have been implemented [<xref ref-type="bibr" rid="CR47">47</xref>]. The sustainable limit of native forests was estimated to be approximately 27,000 tons per year, which would not meet the increasing annual demand [<xref ref-type="bibr" rid="CR48">48</xref>]. The ongoing efforts to address QS-21 supply shortage include: 1) growing more <italic toggle="yes">Quillaja saponaria</italic> Molina trees in plantations [<xref ref-type="bibr" rid="CR49">49</xref>], 2) redistributing the consumption of tree bark from food, cosmetic, and veterinary use to QS-21 extraction, 3) extracting QS-21 from the full biomass of the tree [<xref ref-type="bibr" rid="CR47">47</xref>], 4) extracting QS-21 from leaves of young trees in QS plantations [<xref ref-type="bibr" rid="CR48">48</xref>], 5) improving isolation yield [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>], and 6) producing QS-21 via enzymatic biosynthesis toward a fermenter-based procedure [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Despite the promising progress toward addressing the supply shortage of natural QS-21, other issues persist, notably its dose-limiting toxicity and chemical instability in stock solutions, requiring formulation in liposomes or other nanoparticle constructs such as ISCOMs [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR58">58</xref>]. Thus, development of saponin alternatives to QS-21 that retain its desirable adjuvant activity without its drawbacks - such as a wider therapeutic window, simplified formulation, and improved industrial applicability - is highly desirable.</p></sec><sec id="Sec2"><title>Approaches to developing QS-21 alternatives</title><p id="Par4">There are two potential approaches to developing alternatives to QS-21: mechanism-based molecular design or structure-activity-relationship (SAR)-based exploration. However, the former is not currently feasible due to limitations in our understanding of the molecular mechanism of QS-21. It remains unclear whether QS-21&#8217;s immunostimulating mechanism includes a receptor-dependent component. Prior mechanistic studies indicate that QS-21 does not seem to operate via a depot effect [<xref ref-type="bibr" rid="CR59">59</xref>]. Synthetic QS-21 analogs showed a potential role in facilitating antigen trafficking by antigen-presenting cells (APCs) from the site of injection to the draining lymph nodes (dLNs) [<xref ref-type="bibr" rid="CR60">60</xref>]. In the absence of antigen, Matrix-M<sup>TM</sup> induced a local transient immune response, recruiting and activating central immune cells in dLNs 48&#8201;h after subcutaneous injection [<xref ref-type="bibr" rid="CR61">61</xref>]. Studies show that QS-21 formulated in liposomes targets CD169+ resident macrophages in dLNs [<xref ref-type="bibr" rid="CR62">62</xref>]. It rapidly accumulates in these macrophages, inducing Caspase-1 activation and subsequent events. For instance, it may recruit innate immune cells, activate dendritic cells (DCs), and presumably trigger MyD88-dependent and antigen-specific cellular and humoral responses. It remains unclear whether a QS-21 receptor is involved in these events, although QS-21 is known not to bind to Toll-like receptors 2 and 4 [<xref ref-type="bibr" rid="CR63">63</xref>]. It has been postulated that QS-21 might activate DCs in a receptor-independent manner. For instance, it has been proposed that QS-21 could enhance DCs&#8217; uptake of exogenous protein antigens via cholesterol-dependent endocytosis, and then facilitate antigen escape from endosomes to enhance antigen presentation [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Additionally, QS-21&#8217;s amphiphilic nature can lead to the formation of pores in lysosome membranes, resulting in the release of lysosomal contents and subsequent inflammasome activation and cytokine production. In vitro and in vivo studies have shown that QS-21-containing ISCOMs induce intracellular lipid body (LB) formation specifically in the CD11b<sup>+</sup> dendritic cell (DC) subset [<xref ref-type="bibr" rid="CR66">66</xref>]. This phenomenon enhances the cross-presentation of antigens and subsequent T-cell activation [<xref ref-type="bibr" rid="CR67">67</xref>]. Inflammasomes are frequently targeted by adjuvants due to their ability to stimulate the adaptive immune system [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. Recent investigations have explored whether and how QS-21 activates NOD-like receptor protein 3 (NLRP3) inflammasomes. It appears that only when paired with MPL, QS-21 can activate NLRP3 inflammasomes, leading to IL-1&#946; or IL-18 production in certain immune cells such as bone marrow-derived dendritic cells (BMDCs) or immortalized mouse macrophages. Furthermore, in a case study, QS-21-adjuvanted HIV-1 gp120 induced significantly higher levels of antigen-specific Th1 and Th2 immune responses in NLRP3-deficient mice compared to wild-type controls [<xref ref-type="bibr" rid="CR70">70</xref>]. In another instance, QS-21 in a liposomal formulation activated the NLRP3 inflammasome and produced IL-1&#946; in a Caspase-1-dependent manner [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par5">While the molecular mechanism of QS-21&#8217;s adjuvanticity remains elusive, increasing experimental evidence suggests the presence of molecular targets or receptors for QS-21. For example, two saponin isomers with identical hydrophile-lipophile balance (HLB) can exhibit significantly different adjuvant activities. We compared adjuvant activities of two truncated QS-7 analogs, i.e., <bold>1</bold> and <bold>2</bold> (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). These diastereomers only differ in the stereochemistry of a glycosidic bond within the C28 linear tetrasaccharide. While analog <bold>1</bold> retained considerable adjuvant activity in potentiating antigen specific IgG1 and IgG2a responses, analog <bold>2</bold> lost its adjuvant activity. A similar trend was observed in the comparison between analogs <bold>1</bold> and <bold>3</bold>, where the only structural difference lies in the C28 glycosidic ester bond, with <bold>1</bold> having a beta glycosidic bond (like QS-7 and QS-21) and <bold>3</bold> having an alpha bond. Additionally, two structural isomers, VSA-2 (VO_0005325; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac.niaid.nih.gov/view?id=42">https://vac.niaid.nih.gov/view?id=42</ext-link>) and <bold>4</bold>, which differ only in the terminal functionality of the side chain with a flipped ester group, also demonstrated significantly different adjuvant activities. Studies of these three pairs of isomers suggest that the interaction between a saponin adjuvant and the immune system likely involves a saponin-receptor component; however, the identity of these potential receptors remains unknown.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Structure of three pairs of saponin isomers with significantly different adjuvant activities</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e395" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig1_HTML.jpg"/></fig></p><sec id="Sec3"><title>Structure-activity-relationship studies of QS saponins</title><p id="Par6">Current efforts toward developing QS-21 alternatives primarily focus on SAR studies. QS-21 exhibits hydrolytical instability at physiological pH in stock solutions at ambient temperature. Unlike QS-21, the deacylated byproducts (i.e., QS-21 without the acyl side chain at the C28 fucosyl unit) are incapable of stimulating a Th1 immune response [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. This chemical instability, along with the dose-limiting toxicity, precludes QS-21 from being used alone as an adjuvant. While proper formulations can improve chemical stability and reduce toxicity, the increased complexity in vaccine formulations is not ideal for clinical evaluation and use. Gin&#8217;s laboratory first designed QS-21 analogs equipped with a chemically stable side chain at the original position of the natural side chain [<xref ref-type="bibr" rid="CR73">73</xref>]. They demonstrated that replacing the indicated ester groups with amide moieties did not reduce the adjuvant activity (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Gin&#8217;s laboratory further investigated structurally simplified side chains and found that the array of chiral center within the QS-21 acyl side chain was not essential to maintain adjuvant activity comparable to the natural saponin. Research along this direction, primarily conducted by Gin&#8217;s laboratory and Fernandez-Tejada&#8217;s laboratory, has been highly productive and extensively reviewed [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR79">79</xref>]. Therefore, this review will not focus on that aspect but instead on our previous work concerning QS saponin SAR studies and the discovery of new VSA adjuvants.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Gin&#8217;s SAR studies toward hydrolytically stable QS-21 analogs [<xref ref-type="bibr" rid="CR73">73</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e429" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig2_HTML.jpg"/></fig></p><p id="Par7">In contrast to Gin&#8217;s strategy of developing QS-21 analogs by mimicking the structure of the natural product, i.e., anchoring a simplified side chain at the reducing end of the C28 linear tetrasaccharide, we explored the strategy of incorporating a simple amide side chain at the C3 glucuronic acid site. This strategy was inspired by the success of GPI-0100, a complex mixture of semisynthetic QS derivatives [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. GPI-0100 was derived from Quil A, a partially purified mixture of QS saponins containing QS-17, 18, and 21. Similar to QS-21, Quil A enhances a mixed Th1/Th2 immunity with cytotoxic T lymphocyte (CTL) production. Removal of the side chains of all the side chain-containing components in Quil A (e.g., QS-17, QS-18, and QS-21) under basic conditions results in de-acylated product mixture losing its ability to potentiate a Th1 response [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. However, reintroducing a plain aliphatic side chain (i.e., a dodecylamine side chain), not necessarily in the original acyl side chain position, produces a semisynthetic mixture, GPI-0100, with restored Th1 and CTL capacity [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR83">83</xref>&#8211;<xref ref-type="bibr" rid="CR85">85</xref>]. GPI-0100 exhibits lower immunostimulatory activity and toxicity in mice compared to Quil A and QS-21, allowing for higher doses than natural QS saponins to achieve the desired immune response without early onset of toxicity. However, GPI-0100&#8217;s heterogeneity and variability in content and composition render it unsuitable for clinical use.</p><p id="Par8">We synthesized a series of structurally defined QS analogs to conduct SAR studies (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Among them, saponins <bold>5</bold>&#8211;<bold>7</bold> corresponded to the GPI-0100 components derived from QS-21<sub>api</sub>, QS-21<sub>xyl</sub>, and QS-17/QS-18, respectively. The adjuvant activities of these synthetic saponins were evaluated in female BALB/c mice, with GPI-0100 serving as a positive control. Groups of mice were immunized with rHagB alone or with an adjuvant via the subcutaneous route (<italic toggle="yes">s.c</italic>.). The recombinant antigen rHagB, a non-fimbrial adhesion hemagglutinin B antigen from the periodontal pathogen <italic toggle="yes">Porphyromonas gingivalis</italic>, is effective in inducing an immune response protective against alveolar bone loss in an experimental animal model [<xref ref-type="bibr" rid="CR86">86</xref>]. ELISA analysis indicates that synthetic analogs of QS-21, i.e., saponins <bold>5</bold> and <bold>6</bold>, effectively potentiate and maintain a serum IgG response to rHagB following systemic immunization. However, they exhibit weaker activity than GPI-0100 in boosting serum IgG titers, suggesting that GPI-0100&#8217;s adjuvant activity may instead be attributed to components derived from other QS saponins such as QS-17 and QS-18 [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>].<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Structure of synthetic QS analogs. api &#946;-D-apiofuranosyl, xyl &#946;-D-xylopyranosyl, glc &#946;-D-glucopyranosyl, Ac acetyl</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e501" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig3_HTML.jpg"/></fig></p><p id="Par9">QS-18 is the most abundant component in the mixture of QS Molina tree bark extract. Its structure differs from QS-21 in the C28 oligosaccharide domain, possessing an extra &#946;-D-glucopyranosyl (glc) unit at the C3 hydroxyl group of the &#945;-L-rhamnopyranosyl (rha) unit (i.e., R<sup>2</sup>&#8201;=&#8201;glc, Fig. <xref rid="Fig4" ref-type="fig">4</xref>). On the other hand, QS-17 differs from QS-18 in having a disaccharide unit instead of a monosaccharide unit at the far end of the side chain. QS-17 and QS-18 share the same deacylated residue, thus producing the same analog <bold>7</bold>. Mice immunized with rHagB plus GPI-0100 or rHagB plus analog <bold>7</bold> showed similar IgG1 and IgG2a titers, indicating that QS-17/18 analog <bold>7</bold> is likely the main active component in GPI-0100 [<xref ref-type="bibr" rid="CR87">87</xref>].<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Structure of natural QS saponins and their deacylated counterparts</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e528" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig4_HTML.jpg"/></fig></p><p id="Par10">We further investigated the impact of the side chain structure on adjuvant activity. For instance, to enhance water-solubility, the side chains of analogs <bold>9</bold>&#8211;<bold>13</bold> are equipped with a polar functional group. ELISA analysis revealed that QS-21 analogs <bold>9</bold>&#8211;<bold>11</bold>, and especially <bold>9</bold> and <bold>10</bold>, were effective in potentiating an antigen-specific serum IgG response. The IgG2a/IgG1 ratio of the anti-rHagB responses suggested that rHagB selectively induced a Th2-skewed response following subcutaneous immunization, while GPI-0100, <bold>9</bold>, and <bold>10</bold> potentiated a mixed Th1 and Th2 response to rHagB, and <bold>11</bold> mainly enhanced a Th2 response [<xref ref-type="bibr" rid="CR88">88</xref>]. Compared with GPI-0100 and analog <bold>7</bold>, both QS-17/18 analogs <bold>12</bold> and <bold>13</bold> with a terminal functionalized side chain induced similar IgG1 titers and relatively lower IgG2a titers [<xref ref-type="bibr" rid="CR89">89</xref>]. Saponin <bold>14</bold> is deacylated QS-17/18 and serves as the synthetic precursor of <bold>7,</bold>
<bold>12</bold>, and <bold>13</bold>. Without a side chain, <bold>14</bold> mainly enhanced IgG1 production; however, by capping the 3-OH and 4-OH of the C28 fucosyl unit with acetyl groups, the newly obtained analog <bold>15</bold> induced similar IgG1 and IgG2a titers to those of QS-21 [<xref ref-type="bibr" rid="CR90">90</xref>], suggesting another approach to accessing potent QS analogs.</p></sec><sec id="Sec4"><title>Discovery of <italic toggle="yes">Momordica</italic> saponin-derived VSA adjuvants</title><p id="Par11">Given the significant difference in adjuvant activity between QS-17/18 and their deacylated counterparts, and the structural similarity between the deacylated QS-17/18 and <italic toggle="yes">Momordica</italic> saponin I (MS I) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>) and II (MS II) (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) [<xref ref-type="bibr" rid="CR91">91</xref>], we hypothesized that incorporating a dodecylamine side chain into the natural MS, the corresponding derivatives would result in adjuvant activity resembling that of analog <bold>3</bold>. MS I/II can be obtained from the readily available seeds of <italic toggle="yes">Momordica cochinchinensis</italic> SPRENG (MC), a widely available perennial plant found in regions such as China and Southeast Asia. In traditional Chinese medicine, the seeds, known as <italic toggle="yes">Mubiezi</italic>, are used for the treatment of various conditions including ulcer, mastitis, carbuncle, anal fistula, hemorrhoids, eczema, and neurodermatitis [<xref ref-type="bibr" rid="CR92">92</xref>].<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Serum anti-OVA antibody responses in mice immunized with OVA alone or with GPI-0100 (100&#8201;&#956;g) or VSA-1 (100&#8201;&#956;g) via the <italic toggle="yes">s.c</italic>. route [<xref ref-type="bibr" rid="CR74">74</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e643" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig5_HTML.jpg"/></fig><fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Serum antibody activity to seven serotypes on Day 42. BALB/c mice (8&#8211;10 weeks of age, six per group) were immunized via the subcutaneous route (s.c.) on days 0, 14 and 28. Serum samples were collected prior to the first immunization and 2 weeks following the last immunization. The pooled serum samples of each group were analyzed by ELISA</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e650" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig6_HTML.jpg"/></fig></p><p id="Par12">The composition of the MC seed extract is relatively simple compared to the QS tree bark extract, with a high abundance of MS I/II. This abundance makes isolation more efficient and cost-effective compared to QS saponins. The structures of MS I/II only differ in their triterpenoid cores, with one having a gypsogenin core and the other having a quillaic acid core, similar to immunostimulatory QS-21 and QS-17/18.</p><p id="Par13">MC seed extracts have been investigated for their adjuvant potentials. For instance, a MC seed extract was recently evaluated in a veterinary vaccine candidate against swine foot-and-mouth disease. MC saponins formulated in an oil emulsion were effective in increasing antigen-specific IgG titers in guinea pigs [<xref ref-type="bibr" rid="CR93">93</xref>]. In another study, MS I/II were compared with other adjuvants in boosting immune responses to a model vaccine containing the F4 fimbriae antigen in chickens. Among the tested adjuvants, Freund&#8217;s adjuvant and Quil A were found to be stronger adjuvants than MS I/II in enhancing IgG response in serum and in egg yolk [<xref ref-type="bibr" rid="CR94">94</xref>]. These results align with observations that the de-acylated QS saponins (e.g., de-acylated QS-17, 18, and 21) with striking structural similarities to MS I/II exhibit reduced adjuvant activities. Therefore, we hypothesize that incorporation of a fatty side chain could potentially transform the weakly active adjuvants MS I/II into potent immunostimulants.</p><p id="Par14">The MS derivatives are synthesized in one step by using a standard amide coupling procedure [<xref ref-type="bibr" rid="CR95">95</xref>], and the MS I derivative, i.e., VSA-1 (VO_0005326; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vac.niaid.nih.gov/view?id=41">https://vac.niaid.nih.gov/view?id=41</ext-link>), shows promising adjuvant properties (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). In the initial immunological evaluations of VSA-1 as an adjuvant, we used the antigen-specific IgG1 and IgG2a titers as a tentative indication of enhancement of Th2 and Th1 immunity by an adjuvant, given that Th2- or Th1-related cytokines will enhance production of IgG1 or IgG2a, respectively, in BALB/c mice [<xref ref-type="bibr" rid="CR64">64</xref>]. VSA-1 potentiated antigen-specific IgG1 and IgG2a immune responses that were similar to those induced by GPI-0100, suggesting the similarity between VSA-1 and GPI-0100 in inducing a mixed Th1/Th2 immune response (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Toxicity studies revealed that VSA-1 was significantly less toxic than the natural QS saponins. For example, in an acute toxicity study [<xref ref-type="bibr" rid="CR95">95</xref>], female BALB/c mice (10 weeks of age) were injected subcutaneously with an adjuvant in 0.1&#8201;mL of PBS on the neck. All the mice in the groups treated with VSA-1 (5000&#8201;&#956;g) or Quil-A (100&#8201;&#956;g or more) died within five days post injection. None of the surviving mice (i.e., with a dose of 2000&#8201;&#956;g VSA-1 or less) appeared lethargic by day 7, and no lesion formation was observed. The data indicate that the acute toxicity of VSA-1 is similar to that of GPI-0100 but much lower than that of Quil A.</p><p id="Par15">Recently, we compared VSA-1 and QS-21 in enhancing the clinical glycoconjugate pneumococcal vaccine PCV13 (Prevnar 13 by Pfizer) in mice [<xref ref-type="bibr" rid="CR96">96</xref>]. <italic toggle="yes">Streptococcus pneumoniae</italic> is a pathogen which causes bacterial pneumonia and meningitis, leading to approximately 660,000/year lower respiratory tract infection-related deaths and 9600/year meningitis-related deaths in adults over 50 years old globally, with high mortality rates in the very young, the elderly, and immunocompromised individuals [<xref ref-type="bibr" rid="CR97">97</xref>]. Vaccines are deemed effective in preventing infections by <italic toggle="yes">S. pneumoniae</italic>. PCV13 is composed of purified capsular polysaccharides of 13 serotypes of <italic toggle="yes">S. pneumoniae</italic> (<italic toggle="yes">i.e</italic>., serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 18C, and 23F) individually conjugated to the diphtheria toxin protein carrier CRM197 [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. In all age groups, the administration of PCV13 substantially reduced invasive pneumococcal disease (IPD) caused by the serotypes contained within PCV13. However, the effectiveness of IPD reduction varies depending on the serotype and age group. For instance, serotype 3 is associated with the majority of vaccine breakthroughs in children [<xref ref-type="bibr" rid="CR100">100</xref>&#8211;<xref ref-type="bibr" rid="CR103">103</xref>], while in other cases, serotypes 14 and 19A are responsive for the breakthrough infections [<xref ref-type="bibr" rid="CR104">104</xref>&#8211;<xref ref-type="bibr" rid="CR107">107</xref>]. Another notable challenge with current pneumococcal vaccines is immunosenescence. Therefore, enhancing the efficacy of PCVs is imperative. To address this, we conducted experiments with groups of BALB/c mice that were subcutaneously immunized with different formulations: saline (negative control), PCV 13 (10% of human dose), PCV13 (10% human dose) combined with QS-21 (20&#8201;&#181;g), or PCV 13 (10% of human dose) combined with VSA-1 (100&#8201;&#181;g) on days 0, 14 and 28. ELISA analysis demonstrated that PCV13 effectively elicited antigen-specific antibody responses against the seven selected PCV13 serotypes, i.e., 3, 4, 6B, 9V, 14, 19A, and 19F (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) [<xref ref-type="bibr" rid="CR108">108</xref>]. Comparatively, both VSA-1 and QS-21 augmented PCV13-induced antibody responses across these serotypes compared to the PCV13 control group. While their adjuvant activities were similar for serotypes 3, 6B, 9V, 19A, and 19F, VSA-1 outperformed QS-21 for serotypes 4 and 14.</p><p id="Par16">Since opsonic antibodies play a crucial role in PCV-induced immune protection against encapsulated <italic toggle="yes">S. pneumoniae</italic> [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>], the opsonophagocytosis assay (OPA) was utilized in this study to assess the capacity of sera to kill the bacteria [<xref ref-type="bibr" rid="CR108">108</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>]. The OPA data agrees with the ELISA analysis and confirms that the saponin adjuvants are compatible with PCV13 formulation and can effectively improve the vaccine&#8217;s efficacy. Both VSA-1 and QS-21 could elevate titers of IgG and OPA for the tested serotypes, including the serotypes that cause PCV13 breakthroughs, such as serotypes 3, 14, and 19A. However, VSA-1 leads to higher opsonic antibody titers for serotypes 4, 6B, 14, and 19A than QS-21 does. Given its advantages over QS-21 (e.g., easy access, sustainable supplies, low toxicity, and high chemical stability), VSA-1 can be a practical immunostimulant to be formulated in a new glycoconjugate pneumococcal vaccine.</p><p id="Par17">Recently, VSA-1, QS-21, and alum were compared for their capacity to enhance the protection induced by an inactivated split influenza virus vaccine in a mouse study [<xref ref-type="bibr" rid="CR111">111</xref>]. Seasonal influenza viruses infect 5&#8211;15% of the global population and contribute to up to 650,000 deaths each year [<xref ref-type="bibr" rid="CR112">112</xref>]. Although seasonal influenza vaccines can help limit the spread of the influenza virus, there is a high demand for a universal influenza vaccine with effective cross-protection to address challenges posed by continual influenza virus mutation and the threat of another pandemic [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. A potent immunostimulant is an indispensable vaccine component in achieving this goal. In a recent study, Kang&#8217;s laboratory demonstrated that VSA-1 increased the magnitude of virus-specific IgG antibodies and HAI titers induced by an adjuvanted split (sCal) vaccine in C57BL/6 mice after a single dose. Both the VSA-1- or QS-21-adjuvanted vaccines induced higher levels of virus-specific IgG, including HA stalk-specific IgG antibodies, than the alum-adjuvanted vaccine and the vaccine without an adjuvant after prime immunization. However, VSA-1 is more potent than QS-21 in boosting virus-specific IgG1 and IgG2b titers, as well as HAI titers. Specifically, the VSA-1 group exhibited a 2-fold higher HAI titer than the QS-21 group. VSA-1 is similar to QS-21 in boosting IgG2c isotype antibodies. The same study further demonstrated that VSA-1 enhances vaccine-induced protection against homologous influenza virus in mice. Over a period of 14 days after immunization, the VSA-1-adjuvanted group exhibited a 100% survival rate, the least weight loss (approximately 10%), and a rapid recovery to normal weight. Another aspect of vaccine effectiveness assessment is whether it can induce long-lived antibody-secreting cell (ASC) responses. To address this, the study demonstrated that pathogen challenging led to enhanced ASC and IFN-&#947;-producing T cell responses in the VSA-1-adjuvanted group. Specifically, the VSA-1 group generated more IFN-&#947;-producing cells than the alum or QS-21 groups.</p><p id="Par18">The study also evaluated the effect of boost immunization with VSA-1-adjuvanted influenza vaccine. The results demonstrated that boost immunization with VSA-1- or QS-21-adjuvanted vaccine produced higher titers of virus-specific IgG, IgG1, IgG2b, and IgG2c antibodies compared to the other groups. The levels of HAI titers at 2 weeks post-boost in mice followed the order of VSA-1&#8201;&gt;&#8201;QS-21&#8201;&gt;&#8201;alum&#8201;&gt;&#8201;no adjuvant. Furthermore, VSA-1-adjuvanted boost immunization not only further improved homologous protection but also provided cross-protection against the heterosubtypic rgH5N1 virus.</p><p id="Par19">In the heterosubtypic challenge study, the VSA-1- and QS-21-adjuvanted groups exhibited the highest levels of IgG antibodies after boost, capable of binding the rgH5N1 virus and HA stalk. The VSA-1-adjuvanted group achieved a 100% survival rate, experienced minimal weight loss (approximately 5%), and rapidly recovered to normal weight by day 8 post-challenge. On day 6 after challenge, both the VSA-1 and QS-21 groups displayed virus titers that were 100-fold lower than the na&#239;ve infection control group, and approximately 10-fold lower than the un-adjuvanted vaccine group.</p><p id="Par20">Regarding the impact of boost immunization on cellular responses, the data indicated that the VSA-1-adjuvanted Prime-Boost vaccination regimen further enhanced ASC and IFN-&#947;-producing T cell responses upon virus infection. The regimen induced T cell-dependent protection against heterosubtypic rgH5N1 virus; the VSA-1- and QS-21-adjuvanted groups exhibited higher levels of IFN-&#947;<sup>+</sup> and TNF-&#945;<sup>+</sup>-CD4<sup>+</sup> T and CD8<sup>+</sup> T cells from lung and spleen tissues compared to the other control groups on day 6 post-challenge with the rgH5N1 virus.</p><p id="Par21">Interestingly, by incorporating the same dodecyl amine side chain in natural saponin MS II, the resulting semisynthetic saponin <bold>16</bold> differs from VSA-1 in adjuvant activity, despite their difference solely at the C16 position of the triterpene core (Fig. <xref rid="Fig6" ref-type="fig">6</xref>). Specifically, saponin <bold>16</bold> features a quillaic acid core, while VSA-1 possesses a gypsogenin core. In a head-to-head comparison, VSA-1 and <bold>16</bold> exhibited similar activity in boosting an antigen-specific IgG1 response, but only VSA-1 showed activity in enhancing the IgG2a response. To potentiate the antigen-induced IgG2a response with a MS II-derived semisynthetic saponin, the dodecyl amine side chain was replaced with a new side chain - a 11-aminoundecanoic acid benzyl ester chain - using the same coupling reaction conditions employed for VSA-1 preparation (Fig. <xref rid="Fig7" ref-type="fig">7</xref>).<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Structure of MS II derivatives <bold>16</bold> and VSA-2</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e803" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig7_HTML.jpg"/></fig></p><p id="Par22">The newly obtained saponin adjuvant, VSA-2, was compared with QS-21 in BALB/c mice to assess their capacities for enhancing serum antibody production. The levels of serum antigen-specific antibody activity were determined by ELISA (Fig. <xref rid="Fig8" ref-type="fig">8</xref>). These results revealed that VSA-2 and QS-21 similarly potentiated antigen-specific IgG, IgG1, and IgG2a antibody responses [<xref ref-type="bibr" rid="CR115">115</xref>].<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Serum IgG, IgG1, and IgG2a anti-OVA responses in mice immunized by the <italic toggle="yes">s.c</italic>. route with OVA (20.0&#8201;&#181;g) alone or with OVA (20.0&#8201;&#181;g) in combination with QS-21 (20.0&#8201;&#181;g) or VSA-1 (50.0&#8201;&#181;g) on days 0, 14 and 28 [<xref ref-type="bibr" rid="CR96">96</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e825" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig8_HTML.jpg"/></fig></p><p id="Par23">We also collected mouse spleen cells at week 6 post-immunization and analyzed the cellular responses using flow cytometry. VSA-2- and QS-21-adjuvanted groups exhibited higher surface expression of PD-1 (programmed cell death protein 1) and intracellular levels of IFN-&#947; in both CD8<sup>+</sup> T cells and CD4<sup>+</sup> effector T cells (T<sub>eff</sub>). Moreover, these groups showed higher expression of granzyme B in CD8<sup>+</sup> T cells and higher expression of IL-4 and IL-21 in CD4<sup>+</sup> T<sub>eff</sub> cells compared to the antigen-alone group (Fig. <xref rid="Fig9" ref-type="fig">9</xref>). The preferential increase in IFN-&#947; over IL-4 in the VSA-2 and QS-21 groups suggested that the saponin adjuvants induced a Th1-skewed immune response.<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Analysis of mouse spleen cells: CD8<sup>+</sup> T-cell surface expression of PD-1 (<bold>A</bold>), intracellular levels of IFN&#947; in CD8<sup>+</sup> T-cells (<bold>B</bold>), expression of granzyme B in CD8<sup>+</sup> T-cells (<bold>C</bold>), CD4<sup>+</sup> T-cell surface expression of PD-1 (<bold>D</bold>), intracellular levels of IFN-&#947; in CD4<sup>+</sup> T-cells (<bold>E</bold>), expression of IL-4 in CD4<sup>+</sup> T-cells (<bold>F</bold>), and expression of IL-21 CD4<sup>+</sup> T-cells (<bold>G</bold>) [<xref ref-type="bibr" rid="CR96">96</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e891" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig9_HTML.jpg"/></fig></p><p id="Par24">B cells are responsible for antibody production, which is regulated by follicular helper T cells (T<sub>FH</sub>) and follicular regulatory T cells (T<sub>FR</sub>) [<xref ref-type="bibr" rid="CR116">116</xref>&#8211;<xref ref-type="bibr" rid="CR118">118</xref>]. T<sub>FH</sub> cells aid germinal center (GC) B-cells in producing high-affinity antibodies, whereas T<sub>FR</sub> cells suppresses such activity. Analysis of mouse spleen cells revealed that the VSA-2- and QS-21-adjuvanted groups exhibited higher T<sub>FH</sub> populations (PD-1<sup>+</sup>Bcl6<sup>+</sup>Foxp3<sup>-</sup>CD4<sup>+</sup>CD3<sup>+</sup>) and CD19<sup>+</sup> B-cell populations (Fig. <xref rid="Fig10" ref-type="fig">10D</xref>), along with lower T<sub>FR</sub> cell populations (PD-1<sup>+</sup>Bcl6<sup>+</sup>Foxp3<sup>+</sup>CD4<sup>+</sup>CD3<sup>+</sup>) (Fig. <xref rid="Fig10" ref-type="fig">10B</xref>) compared to the antigen-only group. Correspondingly, the saponin-adjuvanted groups demonstrated higher ratios of T<sub>FH</sub> cells to T<sub>FR</sub> cells than the antigen-only control group (Fig. <xref rid="Fig10" ref-type="fig">10C</xref>). Additionally, the proportions of dark zone GC B-cells (CXCR4<sup>hi</sup>CD86<sup>lo</sup>Fas<sup>+</sup>GL-7<sup>+</sup>CD19<sup>+</sup>) were higher in both the VSA-2 and QS-21 groups than in the antigen-only group (Fig. <xref rid="Fig10" ref-type="fig">10E</xref>). It is recognized that dark zone GC B-cells (CXCR4<sup>hi</sup>CD86<sup>lo</sup>Fas<sup>+</sup>GL-7<sup>+</sup>CD19<sup>+</sup>) are responsible for the producing high-affinity antibodies [<xref ref-type="bibr" rid="CR119">119</xref>]. These findings suggest that VSA-2 and QS-21 exhibit similar abilities to enhance strong cellular and humoral antibody responses.<fig id="Fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>Analysis of mouse spleen cells: T<sub>FH</sub> cells (<bold>A</bold>), T<sub>FR</sub> cells (<bold>B</bold>), ratio of T<sub>FH</sub> to T<sub>RF</sub> (<bold>C</bold>), CD19<sup>+</sup> B-cells (<bold>D</bold>), and dark zone B-cells (<bold>E</bold>) [<xref ref-type="bibr" rid="CR96">96</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1015" position="float" orientation="portrait" xlink:href="44_2024_3227_Fig10_HTML.jpg"/></fig></p></sec></sec><sec id="Sec5"><title>Continuous phytochemical efforts in searching for immunostimulatory natural saponins</title><p id="Par25">Saponins are widely utilized in the food, pharmaceutical, cosmetic industries, and in phytotherapy [<xref ref-type="bibr" rid="CR120">120</xref>&#8211;<xref ref-type="bibr" rid="CR124">124</xref>]. Alongside medicinal chemistry endeavors to develop a new generation of saponin adjuvants, there have been continuous efforts in phytochemical screenings of natural saponins from various sources to discover more natural saponin immunostimulants. This has led to the discovery of numerous saponins with varying degrees of immunostimulating activities, with some of the immunologically active natural saponins are listed in Table <xref rid="Tab1" ref-type="table">1</xref>. Despite extensive phytochemical efforts, natural saponins with adjuvant properties comparable to QS-21 remain elusive.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Natural sources of saponins with immunostimulatory activities</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Order</th><th colspan="1" rowspan="1">Family</th><th colspan="1" rowspan="1">Species</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Apiales</td><td colspan="1" rowspan="1">Araliaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Hedera taurica</italic> [<xref ref-type="bibr" rid="CR125">125</xref>]<italic toggle="yes">, Panax ginseng</italic> [<xref ref-type="bibr" rid="CR126">126</xref>&#8211;<xref ref-type="bibr" rid="CR129">129</xref>], <italic toggle="yes">Panax notoginseng</italic> [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td colspan="1" rowspan="1">Asparagales</td><td colspan="1" rowspan="1">Asparagaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Asparagus racemosus</italic> [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>], <italic toggle="yes">Ophiopogon japonicus</italic> [<xref ref-type="bibr" rid="CR134">134</xref>], <italic toggle="yes">Asparagus adscendens</italic> [<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Iridaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Crocus sativus or saffron</italic> [<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td colspan="1" rowspan="1">Asterales</td><td colspan="1" rowspan="1">Campanulaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Platycodon grandiflorum</italic> [<xref ref-type="bibr" rid="CR137">137</xref>&#8211;<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td colspan="1" rowspan="1">Caryophyllales</td><td colspan="1" rowspan="1">Amaranthaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Achyranthes bidentata</italic> [<xref ref-type="bibr" rid="CR140">140</xref>], <italic toggle="yes">Bupleurum rigidum</italic> [<xref ref-type="bibr" rid="CR141">141</xref>]<italic toggle="yes">, Chenopodium quinoa</italic> [<xref ref-type="bibr" rid="CR142">142</xref>]</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Caryophyllaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Acanthophyllum gypsophiloides</italic> [<xref ref-type="bibr" rid="CR143">143</xref>], <italic toggle="yes">Acanthophyllum squarrosum</italic> [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>]<italic toggle="yes">, Allochrusa gypsophiloides</italic> [<xref ref-type="bibr" rid="CR146">146</xref>], <italic toggle="yes">Gypsophila oldhamiana</italic> [<xref ref-type="bibr" rid="CR147">147</xref>], <italic toggle="yes">Gypsophila paniculata</italic> [<xref ref-type="bibr" rid="CR146">146</xref>]<italic toggle="yes">, Saponaria officinalis</italic> [<xref ref-type="bibr" rid="CR146">146</xref>]<italic toggle="yes">, Silene jenisseensis</italic> [<xref ref-type="bibr" rid="CR148">148</xref>]</td></tr><tr><td colspan="1" rowspan="1">Cucurbitales</td><td colspan="1" rowspan="1">Cucurbitaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Bolbostemma paniculatum</italic> [<xref ref-type="bibr" rid="CR149">149</xref>]<italic toggle="yes">, Gynostemma pentaphyllum</italic> [<xref ref-type="bibr" rid="CR150">150</xref>]</td></tr><tr><td colspan="1" rowspan="1">Dipsacales</td><td colspan="1" rowspan="1">Caprifoliaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Cephalaria sumbuliana</italic> [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]</td></tr><tr><td colspan="1" rowspan="1">Ericales</td><td colspan="1" rowspan="1">Theaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Camellia sinensis</italic> [<xref ref-type="bibr" rid="CR153">153</xref>]</td></tr><tr><td colspan="1" rowspan="1">Fabales</td><td colspan="1" rowspan="1">Fabaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Abrus cantoniensis</italic> [<xref ref-type="bibr" rid="CR154">154</xref>], <italic toggle="yes">Albizia julibrissin</italic> [<xref ref-type="bibr" rid="CR155">155</xref>], <italic toggle="yes">Astragalus membranaceus or brachycalyx</italic> [<xref ref-type="bibr" rid="CR156">156</xref>&#8211;<xref ref-type="bibr" rid="CR163">163</xref>], <italic toggle="yes">Calliandra pulcherrima</italic> [<xref ref-type="bibr" rid="CR164">164</xref>]<italic toggle="yes">, Dolichos Lablab</italic> [<xref ref-type="bibr" rid="CR165">165</xref>], <italic toggle="yes">Glycine max</italic> [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]<italic toggle="yes">, Glycyrrhiza glabra</italic> [<xref ref-type="bibr" rid="CR168">168</xref>]<italic toggle="yes">, Glycyrrhiza inflata, and Glycyrrhiza uralensis</italic> [<xref ref-type="bibr" rid="CR169">169</xref>&#8211;<xref ref-type="bibr" rid="CR171">171</xref>], <italic toggle="yes">Periandra dulcis</italic> [<xref ref-type="bibr" rid="CR172">172</xref>], <italic toggle="yes">Trigonella</italic> [<xref ref-type="bibr" rid="CR165">165</xref>]</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Mimosoideae</td><td colspan="1" rowspan="1"><italic toggle="yes">Acacia concinna</italic> [<xref ref-type="bibr" rid="CR173">173</xref>]</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Polygalaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Polygala japonica</italic> [<xref ref-type="bibr" rid="CR174">174</xref>]<italic toggle="yes">, Polygala senega</italic> [<xref ref-type="bibr" rid="CR175">175</xref>], <italic toggle="yes">Polygala tenuifolia</italic> [<xref ref-type="bibr" rid="CR174">174</xref>]</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Quillajaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Quillaja brasiliensis</italic> [<xref ref-type="bibr" rid="CR176">176</xref>&#8211;<xref ref-type="bibr" rid="CR178">178</xref>]</td></tr><tr><td colspan="1" rowspan="1">Ranunculales</td><td colspan="1" rowspan="1">Ranunculaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Pulsatilla chinensis</italic> [<xref ref-type="bibr" rid="CR179">179</xref>]</td></tr><tr><td colspan="1" rowspan="1">Sapindales</td><td colspan="1" rowspan="1">Sapindaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Aesculus hippocastanum</italic> [<xref ref-type="bibr" rid="CR165">165</xref>]</td></tr><tr><td colspan="1" rowspan="1">Solanales</td><td colspan="1" rowspan="1">Solanaceae</td><td colspan="1" rowspan="1"><italic toggle="yes">Physalis alkekengi</italic> [<xref ref-type="bibr" rid="CR180">180</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6" sec-type="conclusion"><title>Conclusions</title><p id="Par26">Extensive SAR studies of saponins suggest that incorporating an amide side chain to immunologically inactive or weakly active saponins is a viable approach for generating robust immunostimulants. Natural bisdesmosidic saponin precursors, such as <italic toggle="yes">Momordica</italic> saponins, can be conveniently obtained from sustainable sources. This strategy not only helps address the supply shortage of QS-21 but also provides an opportunity to access a broad range of structurally defined and homogenous saponin adjuvants. These adjuvants can complement QS-21 with different adjuvant properties to meet the requirements of various vaccine applications. Furthermore, semisynthetic saponin adjuvants offer new opportunities for developing molecular probes crucial for the exploration of the molecular mechanism underlying saponins&#8217; adjuvanticity. They also facilitate the development of various chemical combinations of adjuvants and built-in adjuvants, thereby enabling the creation of multicomponent synthetic vaccines.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Di Bai, Hyunjung Kim</p></fn></fn-group><ack><title>Acknowledgements</title><p>This research was funded by GM120159 and AI099407 of NIH and 1ARDEF22 10 of the State of Alabama.</p></ack><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par27">The authors declare the following competing financial interest(s): PW is an inventor on the patents and patent applications based on this work. The University of Alabama at Birmingham (UAB) has intellectual property rights to VSA adjuvants developed in PW&#8217;s laboratory. PW is a co-founder of Adjuvax LLC.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines). 2015;3:320&#8211;43.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id><pub-id pub-id-type="pmid">26343190</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>DT</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>LR</given-names></name><name name-style="western"><surname>Hanon</surname><given-names>E</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group><article-title>Towards an evidence based approach for the development of adjuvanted vaccines</article-title><source>Curr Opin Immunol</source><year>2017</year><volume>47</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2017.07.010</pub-id><pub-id pub-id-type="pmid">28755542</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">O&#8217;Hagan DT, Friedland LR, Hanon E, Didierlaurent AM. Towards an evidence based approach for the development of adjuvanted vaccines. Curr Opin Immunol. 2017;47:93&#8211;102.<pub-id pub-id-type="pmid">28755542</pub-id><pub-id pub-id-type="doi">10.1016/j.coi.2017.07.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Gar&#231;on N, Leroux-Roels G, Cheng W-F. Vaccine Adjuvants. In: Gar&#231;on N, Stern PL, Cunningham AL, editors. Understanding Modern Vaccines Perspectives in Vaccinology 1. Amsterdam: Elsevier; 2011. p. 89&#8211;113.</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giudice</surname><given-names>GD</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group><article-title>Correlates of adjuvanticity: A review on adjuvants in licensed vaccines</article-title><source>Semin Immunol</source><year>2018</year><volume>2018</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Giudice GD, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;2018:14&#8211;21.<pub-id pub-id-type="doi">10.1016/j.smim.2018.05.001</pub-id><pub-id pub-id-type="pmid">29801750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3167</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id><pub-id pub-id-type="pmid">31047671</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37:3167&#8211;78.<pub-id pub-id-type="pmid">31047671</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singleton</surname><given-names>KL</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>A</given-names></name><name name-style="western"><surname>Leitner</surname><given-names>WW</given-names></name></person-group><article-title>Review: Current trends, challenges, and success stories in adjuvant research</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1105655</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1105655</pub-id><pub-id pub-id-type="pmid">36742311</pub-id><pub-id pub-id-type="pmcid">PMC9892189</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Singleton KL, Joffe A, Leitner WW. Review: Current trends, challenges, and success stories in adjuvant research. Front Immunol. 2023;14:1105655.<pub-id pub-id-type="pmid">36742311</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1105655</pub-id><pub-id pub-id-type="pmcid">PMC9892189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Laupeze</surname><given-names>B</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A</given-names></name><name name-style="western"><surname>Hergli</surname><given-names>N</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N</given-names></name></person-group><article-title>Adjuvant system AS01: helping to overcome the challenges of modern vaccines</article-title><source>Expert Rev Vaccines</source><year>2017</year><volume>16</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id><pub-id pub-id-type="pmid">27448771</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55&#8211;63.<pub-id pub-id-type="pmid">27448771</pub-id><pub-id pub-id-type="doi">10.1080/14760584.2016.1213632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>SF</given-names></name><name name-style="western"><surname>Chahine</surname><given-names>EB</given-names></name><name name-style="western"><surname>Sucher</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>C</given-names></name></person-group><article-title>Shingrix: the new adjuvanted recombinant herpes zoster vaccine</article-title><source>Ann Pharmacotherapy</source><year>2018</year><volume>52</volume><fpage>673</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1177/1060028018758431</pub-id><pub-id pub-id-type="pmid">29457489</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. Ann Pharmacotherapy. 2018;52:673&#8211;80.<pub-id pub-id-type="doi">10.1177/1060028018758431</pub-id><pub-id pub-id-type="pmid">29457489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lovgren Bengtsson</surname><given-names>K</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation</article-title><source>Expert Rev Vaccines</source><year>2011</year><volume>10</volume><fpage>401</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id><pub-id pub-id-type="pmid">21506635</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10:401&#8211;3.<pub-id pub-id-type="pmid">21506635</pub-id><pub-id pub-id-type="doi">10.1586/erv.11.25</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Altenburg</surname><given-names>AF</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>RD</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice</article-title><source>Immunol Res</source><year>2018</year><volume>66</volume><fpage>224</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s12026-018-8991-x</pub-id><pub-id pub-id-type="pmid">29594879</pub-id><pub-id pub-id-type="pmcid">PMC5899102</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Magnusson SE, Altenburg AF, Bengtsson KL, Bosman F, de Vries RD, Rimmelzwaan GF, et al. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66:224&#8211;33.<pub-id pub-id-type="pmid">29594879</pub-id><pub-id pub-id-type="doi">10.1007/s12026-018-8991-x</pub-id><pub-id pub-id-type="pmcid">PMC5899102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stertman</surname><given-names>L</given-names></name><name name-style="western"><surname>Palm</surname><given-names>AE</given-names></name><name name-style="western"><surname>Zarnegar</surname><given-names>B</given-names></name><name name-style="western"><surname>Carow</surname><given-names>B</given-names></name><name name-style="western"><surname>Lunderius Andersson</surname><given-names>C</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></name><etal/></person-group><article-title>The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century</article-title><source>Hum Vaccines Immunotherapeutics</source><year>2023</year><volume>19</volume><fpage>2189885</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2189885</pub-id><pub-id pub-id-type="pmcid">PMC10158541</pub-id><pub-id pub-id-type="pmid">37113023</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, et al. The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century. Hum Vaccines Immunotherapeutics. 2023;19:2189885.<pub-id pub-id-type="doi">10.1080/21645515.2023.2189885</pub-id><pub-id pub-id-type="pmcid">PMC10158541</pub-id><pub-id pub-id-type="pmid">37113023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2320</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383:2320&#8211;32.<pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutter</surname><given-names>JN</given-names></name><name name-style="western"><surname>Robben</surname><given-names>PM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C</given-names></name><name name-style="western"><surname>Hamer</surname><given-names>M</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JE</given-names></name><name name-style="western"><surname>Merino</surname><given-names>K</given-names></name><etal/></person-group><article-title>First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>5781</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.08.048</pub-id><pub-id pub-id-type="pmid">36055874</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Hutter JN, Robben PM, Lee C, Hamer M, Moon JE, Merino K, et al. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults. Vaccine. 2022;40:5781&#8211;90.<pub-id pub-id-type="pmid">36055874</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.08.048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>J</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AS</given-names></name><name name-style="western"><surname>Pride</surname><given-names>MW</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>KU</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50&#8211;85 years</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>5991</fpage><lpage>6003</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.028</pub-id><pub-id pub-id-type="pmid">34483022</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lawrence J, Kitchin N, Anderson AS, Pride MW, Jansen KU, Gruber WC, et al. Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50&#8211;85 years. Vaccine. 2021;39:5991&#8211;6003.<pub-id pub-id-type="pmid">34483022</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melssen</surname><given-names>MM</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>KE</given-names></name><name name-style="western"><surname>Meneveau</surname><given-names>MO</given-names></name><name name-style="western"><surname>Smolkin</surname><given-names>ME</given-names></name><name name-style="western"><surname>Pinczewski</surname><given-names>J</given-names></name><name name-style="western"><surname>Koeppel</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><fpage>2151</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02844-w</pub-id><pub-id pub-id-type="pmid">33454795</pub-id><pub-id pub-id-type="pmcid">PMC10992166</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Melssen MM, Pollack KE, Meneveau MO, Smolkin ME, Pinczewski J, Koeppel AF, et al. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Cancer Immunol Immunother. 2021;70:2151&#8211;64.<pub-id pub-id-type="pmid">33454795</pub-id><pub-id pub-id-type="doi">10.1007/s00262-020-02844-w</pub-id><pub-id pub-id-type="pmcid">PMC10992166</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Smedt</surname><given-names>P</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G</given-names></name><name name-style="western"><surname>Vandermeulen</surname><given-names>C</given-names></name><name name-style="western"><surname>Tasciotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Di Maro</surname><given-names>G</given-names></name><name name-style="western"><surname>Dozot</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial</article-title><source>Vaccine X</source><year>2021</year><volume>9</volume><fpage>100124</fpage><pub-id pub-id-type="doi">10.1016/j.jvacx.2021.100124</pub-id><pub-id pub-id-type="pmid">34820619</pub-id><pub-id pub-id-type="pmcid">PMC8600057</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">De Smedt P, Leroux-Roels G, Vandermeulen C, Tasciotti A, Di Maro G, Dozot M, et al. Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial. Vaccine X. 2021;9:100124.<pub-id pub-id-type="pmid">34820619</pub-id><pub-id pub-id-type="doi">10.1016/j.jvacx.2021.100124</pub-id><pub-id pub-id-type="pmcid">PMC8600057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldwin</surname><given-names>SL</given-names></name><name name-style="western"><surname>Reese</surname><given-names>VA</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>SE</given-names></name><name name-style="western"><surname>Pecor</surname><given-names>T</given-names></name><name name-style="western"><surname>Brown</surname><given-names>BP</given-names></name><name name-style="western"><surname>Granger</surname><given-names>B</given-names></name><etal/></person-group><article-title>Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>935444</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.935444</pub-id><pub-id pub-id-type="pmid">36090093</pub-id><pub-id pub-id-type="pmcid">PMC9459154</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Baldwin SL, Reese VA, Larsen SE, Pecor T, Brown BP, Granger B, et al. Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations. Front Microbiol. 2022;13:935444.<pub-id pub-id-type="pmid">36090093</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.935444</pub-id><pub-id pub-id-type="pmcid">PMC9459154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bender</surname><given-names>NG</given-names></name><name name-style="western"><surname>Khare</surname><given-names>P</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J</given-names></name><name name-style="western"><surname>Tweedell</surname><given-names>RE</given-names></name><name name-style="western"><surname>Nyasembe</surname><given-names>VO</given-names></name><name name-style="western"><surname>Lopez-Gutierrez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00309-4</pub-id><pub-id pub-id-type="pmid">33824336</pub-id><pub-id pub-id-type="pmcid">PMC8024329</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bender NG, Khare P, Martinez J, Tweedell RE, Nyasembe VO, Lopez-Gutierrez B, et al. Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen. NPJ Vaccines. 2021;6:49.<pub-id pub-id-type="pmid">33824336</pub-id><pub-id pub-id-type="doi">10.1038/s41541-021-00309-4</pub-id><pub-id pub-id-type="pmcid">PMC8024329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatnagar</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KH</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>BR</given-names></name><name name-style="western"><surname>Ko</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Seong</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice</article-title><source>Antiviral Res</source><year>2022</year><volume>197</volume><fpage>105229</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2021.105229</pub-id><pub-id pub-id-type="pmid">34933043</pub-id><pub-id pub-id-type="pmcid">PMC8801234</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bhatnagar N, Kim KH, Subbiah J, Park BR, Ko EJ, Seong BL, et al. Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice. Antiviral Res. 2022;197:105229.<pub-id pub-id-type="pmid">34933043</pub-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2021.105229</pub-id><pub-id pub-id-type="pmcid">PMC8801234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>EB</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>RS</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>151</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00414-4</pub-id><pub-id pub-id-type="pmid">34903722</pub-id><pub-id pub-id-type="pmcid">PMC8668928</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Carmen JM, Shrivastava S, Lu Z, Anderson A, Morrison EB, Sankhala RS, et al. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. NPJ Vaccines. 2021;6:151.<pub-id pub-id-type="pmid">34903722</pub-id><pub-id pub-id-type="doi">10.1038/s41541-021-00414-4</pub-id><pub-id pub-id-type="pmcid">PMC8668928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A</given-names></name><name name-style="western"><surname>Lai</surname><given-names>CC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CK</given-names></name><name name-style="western"><surname>Lin</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>3337</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.04.006</pub-id><pub-id pub-id-type="pmid">37085450</pub-id><pub-id pub-id-type="pmcid">PMC10083212</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chang CC, Algaissi A, Lai CC, Chang CK, Lin JS, Wang YS, et al. Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus. Vaccine. 2023;41:3337&#8211;46.<pub-id pub-id-type="pmid">37085450</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.04.006</pub-id><pub-id pub-id-type="pmcid">PMC10083212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellison</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Talbott</surname><given-names>GC</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>DR</given-names></name></person-group><article-title>Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>304</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.10.006</pub-id><pub-id pub-id-type="pmid">36587961</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Ellison TJ, Talbott GC, Henderson DR. Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform. Vaccine. 2023;41:304&#8211;14.<pub-id pub-id-type="pmid">36587961</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.10.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">He L, Sun B, Guo Y, Yan K, Liu D, Zang Y, et al. Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants. Int Immunopharmacol. 2021;101:108216.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2021.108216</pub-id><pub-id pub-id-type="pmid">34634689</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Seffouh</surname><given-names>A</given-names></name><name name-style="western"><surname>Mabrouk</surname><given-names>MT</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>MT</given-names></name><etal/></person-group><article-title>A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8(+) T Cell Epitopes</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>4357</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c07680</pub-id><pub-id pub-id-type="pmid">33606514</pub-id><pub-id pub-id-type="pmcid">PMC10184788</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">He X, Zhou S, Huang WC, Seffouh A, Mabrouk MT, Morgan MT, et al. A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8(+) T Cell Epitopes. ACS Nano. 2021;15:4357&#8211;71.<pub-id pub-id-type="pmid">33606514</pub-id><pub-id pub-id-type="doi">10.1021/acsnano.0c07680</pub-id><pub-id pub-id-type="pmcid">PMC10184788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>JP</given-names></name><name name-style="western"><surname>Xu</surname><given-names>JC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Qu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination</article-title><source>Virology</source><year>2022</year><volume>566</volume><fpage>56</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2021.11.011</pub-id><pub-id pub-id-type="pmid">34864488</pub-id><pub-id pub-id-type="pmcid">PMC8634073</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Hu Z, Chen JP, Xu JC, Chen ZY, Qu R, Zhang L, et al. A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination. Virology. 2022;566:56&#8211;9.<pub-id pub-id-type="pmid">34864488</pub-id><pub-id pub-id-type="doi">10.1016/j.virol.2021.11.011</pub-id><pub-id pub-id-type="pmcid">PMC8634073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>WC</given-names></name><name name-style="western"><surname>Mabrouk</surname><given-names>MT</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Baba</surname><given-names>M</given-names></name><name name-style="western"><surname>Tachibana</surname><given-names>M</given-names></name><name name-style="western"><surname>Torii</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages</article-title><source>Commun Biol</source><year>2022</year><volume>5</volume><fpage>773</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-03688-z</pub-id><pub-id pub-id-type="pmid">35915227</pub-id><pub-id pub-id-type="pmcid">PMC9341416</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Huang WC, Mabrouk MT, Zhou L, Baba M, Tachibana M, Torii M, et al. Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages. Commun Biol. 2022;5:773.<pub-id pub-id-type="pmid">35915227</pub-id><pub-id pub-id-type="doi">10.1038/s42003-022-03688-z</pub-id><pub-id pub-id-type="pmcid">PMC9341416</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Jia Y, Akache B, Agbayani G, Chandan V, Dudani R, Harrison BA, et al. The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model. Pharmaceutics. 2021;13.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13020205</pub-id><pub-id pub-id-type="pmcid">PMC7913188</pub-id><pub-id pub-id-type="pmid">33540932</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">King HAD, Joyce MG, Lakhal-Naouar I, Ahmed A, Cincotta CM, Subra C, et al. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci USA. 2021;118.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2106433118</pub-id><pub-id pub-id-type="pmcid">PMC8463842</pub-id><pub-id pub-id-type="pmid">34470866</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mabrouk</surname><given-names>MT</given-names></name><name name-style="western"><surname>Chiem</surname><given-names>K</given-names></name><name name-style="western"><surname>Rujas</surname><given-names>E</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W-C</given-names></name><name name-style="western"><surname>Jahagirdar</surname><given-names>D</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>B</given-names></name><etal/></person-group><article-title>Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><fpage>eabj1476</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abj1476</pub-id><pub-id pub-id-type="pmid">34851667</pub-id><pub-id pub-id-type="pmcid">PMC8635435</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Mabrouk MT, Chiem K, Rujas E, Huang W-C, Jahagirdar D, Quinn B, et al. Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice. Sci Adv. 2021;7:eabj1476.<pub-id pub-id-type="pmid">34851667</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.abj1476</pub-id><pub-id pub-id-type="pmcid">PMC8635435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Counoupas</surname><given-names>C</given-names></name><name name-style="western"><surname>Nagalingam</surname><given-names>G</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>R</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N</given-names></name><name name-style="western"><surname>Britton</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>1990</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.02.041</pub-id><pub-id pub-id-type="pmid">33714652</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Quan DH, Counoupas C, Nagalingam G, Pinto R, Petrovsky N, Britton WJ, et al. Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine. 2021;39:1990&#8211;6.<pub-id pub-id-type="pmid">33714652</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.02.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sei</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Schuman</surname><given-names>RF</given-names></name><name name-style="western"><surname>Daum</surname><given-names>LT</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name><name name-style="western"><surname>Rikhi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>698</fpage><pub-id pub-id-type="doi">10.3390/vaccines9070698</pub-id><pub-id pub-id-type="pmid">34202178</pub-id><pub-id pub-id-type="pmcid">PMC8310080</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sei CJ, Rao M, Schuman RF, Daum LT, Matyas GR, Rikhi N, et al. Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies. Vaccines. 2021;9:698.<pub-id pub-id-type="pmid">34202178</pub-id><pub-id pub-id-type="doi">10.3390/vaccines9070698</pub-id><pub-id pub-id-type="pmcid">PMC8310080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Carmen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Basu</surname><given-names>S</given-names></name><name name-style="western"><surname>Sankhala</surname><given-names>RS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WH</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies</article-title><source>NPJ Vaccines</source><year>2023</year><volume>8</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00638-6</pub-id><pub-id pub-id-type="pmid">36934088</pub-id><pub-id pub-id-type="pmcid">PMC10024299</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Shrivastava S, Carmen JM, Lu Z, Basu S, Sankhala RS, Chen WH, et al. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies. NPJ Vaccines. 2023;8:43.<pub-id pub-id-type="pmid">36934088</pub-id><pub-id pub-id-type="doi">10.1038/s41541-023-00638-6</pub-id><pub-id pub-id-type="pmcid">PMC10024299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thanvi</surname><given-names>R</given-names></name><name name-style="western"><surname>Nada</surname><given-names>S</given-names></name><name name-style="western"><surname>Dissanayake</surname><given-names>R</given-names></name><name name-style="western"><surname>Vartak</surname><given-names>A</given-names></name><name name-style="western"><surname>Sebilleau</surname><given-names>CO</given-names></name><name name-style="western"><surname>Alom</surname><given-names>NE</given-names></name><etal/></person-group><article-title>Synthesis and Evaluation of a Self-Adjuvanting Pseudomonal Vaccine Based on Major Outer Membrane Porin OprF Epitopes Formulated with Low-Toxicity QS-21-Containing Liposomes</article-title><source>Bioconjug Chem</source><year>2023</year><volume>34</volume><fpage>893</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00103</pub-id><pub-id pub-id-type="pmid">37092892</pub-id><pub-id pub-id-type="pmcid">PMC10723056</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Thanvi R, Nada S, Dissanayake R, Vartak A, Sebilleau CO, Alom NE, et al. Synthesis and Evaluation of a Self-Adjuvanting Pseudomonal Vaccine Based on Major Outer Membrane Porin OprF Epitopes Formulated with Low-Toxicity QS-21-Containing Liposomes. Bioconjug Chem. 2023;34:893&#8211;910.<pub-id pub-id-type="pmid">37092892</pub-id><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.3c00103</pub-id><pub-id pub-id-type="pmcid">PMC10723056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Hegde</surname><given-names>VL</given-names></name><name name-style="western"><surname>Yanamandra</surname><given-names>AV</given-names></name><name name-style="western"><surname>O&#8217;Hara</surname><given-names>MP</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>B</given-names></name><name name-style="western"><surname>Jones</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>800295</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.800295</pub-id><pub-id pub-id-type="pmid">35197976</pub-id><pub-id pub-id-type="pmcid">PMC8859434</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Wei J, Hegde VL, Yanamandra AV, O&#8217;Hara MP, Keegan B, Jones KM, et al. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022;13:800295.<pub-id pub-id-type="pmid">35197976</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.800295</pub-id><pub-id pub-id-type="pmcid">PMC8859434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>YS</given-names></name><name name-style="western"><surname>AboulFotouh</surname><given-names>K</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G</given-names></name><name name-style="western"><surname>Suman</surname><given-names>J</given-names></name><name name-style="western"><surname>Cano</surname><given-names>C</given-names></name><etal/></person-group><article-title>Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders</article-title><source>Int J Pharmaceutics</source><year>2023</year><volume>640</volume><fpage>122990</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.122990</pub-id><pub-id pub-id-type="pmid">37127138</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Yu YS, AboulFotouh K, Xu H, Williams G, Suman J, Cano C, et al. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders. Int J Pharmaceutics. 2023;640:122990.<pub-id pub-id-type="doi">10.1016/j.ijpharm.2023.122990</pub-id><pub-id pub-id-type="pmid">37127138</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juan Shi</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>R</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name></person-group><article-title>Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>713</fpage><pub-id pub-id-type="doi">10.3390/vaccines11040713</pub-id><pub-id pub-id-type="pmid">37112625</pub-id><pub-id pub-id-type="pmcid">PMC10147067</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Juan Shi YZ, Peng M, Zhu S, Wu Y, Ji R, Shen C. Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2. Vaccines. 2023;11:713.<pub-id pub-id-type="pmid">37112625</pub-id><pub-id pub-id-type="doi">10.3390/vaccines11040713</pub-id><pub-id pub-id-type="pmcid">PMC10147067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>KW</given-names></name><name name-style="western"><surname>Kang</surname><given-names>TG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Jin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YT</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Protective Efficacy and Immunogenicity of Rv0351_Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection</article-title><source>Immune Netw</source><year>2023</year><volume>23</volume><fpage>e16</fpage><pub-id pub-id-type="doi">10.4110/in.2023.23.e16</pub-id><pub-id pub-id-type="pmid">37179749</pub-id><pub-id pub-id-type="pmcid">PMC10166659</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kwon KW, Kang TG, Lee A, Jin SM, Lim YT, Shin SJ, et al. Protective Efficacy and Immunogenicity of Rv0351_Rv3628 Subunit Vaccine Formulated in Different Adjuvants Against Mycobacterium tuberculosis Infection. Immune Netw. 2023;23:e16.<pub-id pub-id-type="pmid">37179749</pub-id><pub-id pub-id-type="doi">10.4110/in.2023.23.e16</pub-id><pub-id pub-id-type="pmcid">PMC10166659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>N</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>973</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14050973</pub-id><pub-id pub-id-type="pmid">35631559</pub-id><pub-id pub-id-type="pmcid">PMC9143440</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Luan N, Cao H, Wang Y, Lin K, Liu C. Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine. Pharmaceutics. 2022;14:973.<pub-id pub-id-type="pmid">35631559</pub-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14050973</pub-id><pub-id pub-id-type="pmcid">PMC9143440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JS</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>A</given-names></name><name name-style="western"><surname>Lebas</surname><given-names>C</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>JB</given-names></name><name name-style="western"><surname>Young</surname><given-names>PR</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>V</given-names></name><etal/></person-group><article-title>Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>976968</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.976968</pub-id><pub-id pub-id-type="pmid">36119058</pub-id><pub-id pub-id-type="pmcid">PMC9478912</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">O&#8217;Donnell JS, Isaacs A, Lebas C, Barnes JB, Young PR, Jakob V, et al. Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Front Immunol. 2022;13:976968.<pub-id pub-id-type="pmid">36119058</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.976968</pub-id><pub-id pub-id-type="pmcid">PMC9478912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaria</surname><given-names>PV</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C</given-names></name><name name-style="western"><surname>Muratova</surname><given-names>O</given-names></name><name name-style="western"><surname>Alani</surname><given-names>N</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>HV</given-names></name><name name-style="western"><surname>Nadakal</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>148</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00407-3</pub-id><pub-id pub-id-type="pmid">34887448</pub-id><pub-id pub-id-type="pmcid">PMC8660773</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Scaria PV, Anderson C, Muratova O, Alani N, Trinh HV, Nadakal ST, et al. Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques. NPJ Vaccines. 2021;6:148.<pub-id pub-id-type="pmid">34887448</pub-id><pub-id pub-id-type="doi">10.1038/s41541-021-00407-3</pub-id><pub-id pub-id-type="pmcid">PMC8660773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Stegmann T, Wiekmeijer AS, Kwappenberg K, Duikeren Sv, Bhoelan F, Bemelman D, et al. Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides. Cancer Immunol Immunotherapy. 2023;72:2851&#8211;64.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-023-03462-y</pub-id><pub-id pub-id-type="pmcid">PMC10361876</pub-id><pub-id pub-id-type="pmid">37222770</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Techawiwattanaboon T, Courant T, Brunner L, Sathean-anan-kun S, Krangvichian P, Iadsee N, et al. Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of Leptospira Immunoglobulin-Like Protein A Subunit Vaccine. Front Cell Infect Microbiol. 2022;12:918629.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.918629</pub-id><pub-id pub-id-type="pmcid">PMC9243587</pub-id><pub-id pub-id-type="pmid">35782116</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Yang B, Zhu D, Zhou Y, Gong B, Hu Y, Zhang J, et al. Liposome and QS-21 Combined Adjuvant Induces theHumoral and Cellular Responses of Acellular Pertussis Vaccine in a Mice Model. Vaccines. 2023;11:914.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11050914</pub-id><pub-id pub-id-type="pmcid">PMC10223510</pub-id><pub-id pub-id-type="pmid">37243018</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M-C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C-C</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W-C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K-M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H-H</given-names></name><etal/></person-group><article-title>Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies</article-title><source>PloS One</source><year>2023</year><volume>18</volume><fpage>e0283473</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0283473</pub-id><pub-id pub-id-type="pmid">36961826</pub-id><pub-id pub-id-type="pmcid">PMC10038307</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Yang M-C, Wang C-C, Tang W-C, Chen K-M, Chen C, Lin H-H, et al. Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. PloS One. 2023;18:e0283473.<pub-id pub-id-type="pmid">36961826</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0283473</pub-id><pub-id pub-id-type="pmcid">PMC10038307</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinke</surname><given-names>S</given-names></name><name name-style="western"><surname>Pantazi</surname><given-names>E</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>GR</given-names></name><name name-style="western"><surname>Sanchez-Martinez</surname><given-names>A</given-names></name><name name-style="western"><surname>Guyon</surname><given-names>R</given-names></name><name name-style="western"><surname>Fergusson</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms</article-title><source>Cell Rep Med</source><year>2023</year><volume>4</volume><fpage>101245</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101245</pub-id><pub-id pub-id-type="pmid">37913775</pub-id><pub-id pub-id-type="pmcid">PMC10694591</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Reinke S, Pantazi E, Chappell GR, Sanchez-Martinez A, Guyon R, Fergusson JR, et al. Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms. Cell Rep Med. 2023;4:101245.<pub-id pub-id-type="pmid">37913775</pub-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101245</pub-id><pub-id pub-id-type="pmcid">PMC10694591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>CR</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>GR</given-names></name></person-group><article-title>Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1102524</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1102524</pub-id><pub-id pub-id-type="pmid">36761767</pub-id><pub-id pub-id-type="pmcid">PMC9905621</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Alving CR, Rao M, Matyas GR. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21. Front Immunol. 2023;14:1102524.<pub-id pub-id-type="pmid">36761767</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1102524</pub-id><pub-id pub-id-type="pmcid">PMC9905621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San Martin</surname><given-names>R</given-names></name><name name-style="western"><surname>Briones</surname><given-names>R</given-names></name></person-group><article-title>Industrial uses and sustainable supply of Quillaja Saponaria (Rosaceae) Saponins</article-title><source>Econ Botany</source><year>1999</year><volume>53</volume><fpage>302</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/BF02866642</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">San Martin R, Briones R. Industrial uses and sustainable supply of Quillaja Saponaria (Rosaceae) Saponins. Econ Botany. 1999;53:302&#8211;11.<pub-id pub-id-type="doi">10.1007/BF02866642</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlotterbeck</surname><given-names>T</given-names></name><name name-style="western"><surname>Castillo-Ruiz</surname><given-names>M</given-names></name><name name-style="western"><surname>Ca&#241;on-Jones</surname><given-names>H</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>RS</given-names></name></person-group><article-title>The Use of Leaves from Young Trees of Qui&#252;aja saponaria (Molina) Plantations as a New Source of Saponins</article-title><source>Econ Botany</source><year>2015</year><volume>69</volume><fpage>262</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s12231-015-9320-0</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Schlotterbeck T, Castillo-Ruiz M, Ca&#241;on-Jones H, Mart&#237;n RS. The Use of Leaves from Young Trees of Qui&#252;aja saponaria (Molina) Plantations as a New Source of Saponins. Econ Botany. 2015;69:262&#8211;72.<pub-id pub-id-type="doi">10.1007/s12231-015-9320-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donoso</surname><given-names>S</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>K</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>C</given-names></name><name name-style="western"><surname>Luna</surname><given-names>G</given-names></name><name name-style="western"><surname>Aguirre</surname><given-names>A</given-names></name></person-group><article-title>Respuesta fisiol&#243;gica y de crecimiento en plantas de Quillaja saponaria y Cryptocarya alba sometidas a restricci&#243;n h&#237;drica</article-title><source>Bosque</source><year>2011</year><volume>32</volume><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.4067/S0717-92002011000200009</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Donoso S, Pe&#241;a K, Pacheco C, Luna G, Aguirre A. Respuesta fisiol&#243;gica y de crecimiento en plantas de Quillaja saponaria y Cryptocarya alba sometidas a restricci&#243;n h&#237;drica. Bosque. 2011;32:187&#8211;95.<pub-id pub-id-type="doi">10.4067/S0717-92002011000200009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficient ultrasound-assisted enzymatic method for extraction of immunostimulant QS-21 from Quillaja saponaria Molina</article-title><source>Industrial Crops and Products</source><year>2022</year><volume>189</volume><fpage>115807</fpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2022.115807</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Gao Y, Dong Q, Zhao S, Zhao Y, Zhang Y, Wang H, et al. Efficient ultrasound-assisted enzymatic method for extraction of immunostimulant QS-21 from Quillaja saponaria Molina. Industrial Crops and Products. 2022;189:115807.<pub-id pub-id-type="doi">10.1016/j.indcrop.2022.115807</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fox</surname><given-names>CB</given-names></name></person-group><article-title>A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield</article-title><source>J Chromatogr A</source><year>2021</year><volume>1635</volume><fpage>461705</fpage><pub-id pub-id-type="doi">10.1016/j.chroma.2020.461705</pub-id><pub-id pub-id-type="pmid">33234294</pub-id><pub-id pub-id-type="pmcid">PMC7770036</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Qi Y, Fox CB. A Two-Step Orthogonal Chromatographic Process for Purifying the Molecular Adjuvant QS-21 with High Purity and Yield. J Chromatogr A. 2021;1635:461705.<pub-id pub-id-type="pmid">33234294</pub-id><pub-id pub-id-type="doi">10.1016/j.chroma.2020.461705</pub-id><pub-id pub-id-type="pmcid">PMC7770036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>J</given-names></name><name name-style="western"><surname>Orme</surname><given-names>A</given-names></name><name name-style="western"><surname>El-Demerdash</surname><given-names>A</given-names></name><name name-style="western"><surname>Owen</surname><given-names>C</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LBB</given-names></name><name name-style="western"><surname>Misra</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Elucidation of the pathway for biosynthesis of saponin adjuvants from the soapbark tree</article-title><source>Science</source><year>2023</year><volume>379</volume><fpage>1252</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1126/science.adf3727</pub-id><pub-id pub-id-type="pmid">36952412</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Reed J, Orme A, El-Demerdash A, Owen C, Martin LBB, Misra RC, et al. Elucidation of the pathway for biosynthesis of saponin adjuvants from the soapbark tree. Science. 2023;379:1252&#8211;64.<pub-id pub-id-type="pmid">36952412</pub-id><pub-id pub-id-type="doi">10.1126/science.adf3727</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>LBB</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Rejzek</surname><given-names>M</given-names></name><name name-style="western"><surname>Owen</surname><given-names>C</given-names></name><name name-style="western"><surname>Reed</surname><given-names>J</given-names></name><name name-style="western"><surname>Orme</surname><given-names>A</given-names></name><etal/></person-group><article-title>Complete biosynthesis of the potent vaccine adjuvant QS-21</article-title><source>Nat Chem Biol</source><year>2024</year><volume>20</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/s41589-023-01538-5</pub-id><pub-id pub-id-type="pmid">38278997</pub-id><pub-id pub-id-type="pmcid">PMC10972754</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Martin LBB, Kikuchi S, Rejzek M, Owen C, Reed J, Orme A, et al. Complete biosynthesis of the potent vaccine adjuvant QS-21. Nat Chem Biol. 2024;20:493&#8211;502.<pub-id pub-id-type="pmid">38278997</pub-id><pub-id pub-id-type="doi">10.1038/s41589-023-01538-5</pub-id><pub-id pub-id-type="pmcid">PMC10972754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragupathi</surname><given-names>G</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>PO</given-names></name><name name-style="western"><surname>Gin</surname><given-names>DY</given-names></name></person-group><article-title>Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer</article-title><source>Expert Rev Vaccines</source><year>2011</year><volume>10</volume><fpage>463</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1586/erv.11.18</pub-id><pub-id pub-id-type="pmid">21506644</pub-id><pub-id pub-id-type="pmcid">PMC3658151</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Ragupathi G, Gardner JR, Livingston PO, Gin DY. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines. 2011;10:463&#8211;70.<pub-id pub-id-type="pmid">21506644</pub-id><pub-id pub-id-type="doi">10.1586/erv.11.18</pub-id><pub-id pub-id-type="pmcid">PMC3658151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baz Morelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Becher</surname><given-names>D</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A</given-names></name><name name-style="western"><surname>Drane</surname><given-names>D</given-names></name><name name-style="western"><surname>Maraskovsky</surname><given-names>E</given-names></name></person-group><article-title>ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases</article-title><source>J Med Microbiol</source><year>2012</year><volume>61</volume><fpage>935</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.040857-0</pub-id><pub-id pub-id-type="pmid">22442293</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Baz Morelli A, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol. 2012;61:935&#8211;43.<pub-id pub-id-type="pmid">22442293</pub-id><pub-id pub-id-type="doi">10.1099/jmm.0.040857-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearse</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Drane</surname><given-names>D</given-names></name></person-group><article-title>ISCOMATRIX adjuvant for antigen delivery</article-title><source>Adv Drug Deliv Rev</source><year>2005</year><volume>57</volume><fpage>465</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2004.09.006</pub-id><pub-id pub-id-type="pmid">15560952</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Pearse MJ, Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev. 2005;57:465&#8211;74.<pub-id pub-id-type="pmid">15560952</pub-id><pub-id pub-id-type="doi">10.1016/j.addr.2004.09.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skene</surname><given-names>CD</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>P</given-names></name></person-group><article-title>Saponin-adjuvanted particulate vaccines for clinical use</article-title><source>Methods</source><year>2006</year><volume>40</volume><fpage>53</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2006.05.019</pub-id><pub-id pub-id-type="pmid">16997713</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods. 2006;40:53&#8211;9.<pub-id pub-id-type="pmid">16997713</pub-id><pub-id pub-id-type="doi">10.1016/j.ymeth.2006.05.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>YP</given-names></name></person-group><article-title>ISCOMs and ISCOMATRIX</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4388</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.032</pub-id><pub-id pub-id-type="pmid">19450632</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine. 2009;27:4388&#8211;401.<pub-id pub-id-type="pmid">19450632</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.032</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kensil</surname><given-names>CR</given-names></name></person-group><article-title>Saponins as vaccine adjuvants</article-title><source>Crit Rev Ther Drug Carrier Syst</source><year>1996</year><volume>13</volume><fpage>1</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8853958</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996;13:1&#8211;55.<pub-id pub-id-type="pmid">8853958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Tejada</surname><given-names>A</given-names></name><name name-style="western"><surname>Chea</surname><given-names>EK</given-names></name><name name-style="western"><surname>George</surname><given-names>C</given-names></name><name name-style="western"><surname>Pillarsetty</surname><given-names>N</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Development of a Minimal Saponin Vaccine Adjuvant based on QS-21</article-title><source>Nat Chem</source><year>2014</year><volume>6</volume><fpage>635</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nchem.1963</pub-id><pub-id pub-id-type="pmid">24950335</pub-id><pub-id pub-id-type="pmcid">PMC4215704</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Fern&#225;ndez-Tejada A, Chea EK, George C, Pillarsetty N, Gardner JR, Livingston PO, et al. Development of a Minimal Saponin Vaccine Adjuvant based on QS-21. Nat Chem. 2014;6:635&#8211;43.<pub-id pub-id-type="pmid">24950335</pub-id><pub-id pub-id-type="doi">10.1038/nchem.1963</pub-id><pub-id pub-id-type="pmcid">PMC4215704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reimer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>KH</given-names></name><name name-style="western"><surname>Lovgren-Bengtsson</surname><given-names>K</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>SE</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>A</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L</given-names></name></person-group><article-title>Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen</article-title><source>PloS One</source><year>2012</year><volume>7</volume><fpage>e41451</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0041451</pub-id><pub-id pub-id-type="pmid">22844480</pub-id><pub-id pub-id-type="pmcid">PMC3402407</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Reimer JM, Karlsson KH, Lovgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PloS One. 2012;7:e41451.<pub-id pub-id-type="pmid">22844480</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041451</pub-id><pub-id pub-id-type="pmcid">PMC3402407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detienne</surname><given-names>S</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>M</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S</given-names></name><etal/></person-group><article-title>Central Role of CD169(+) Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>39475</fpage><pub-id pub-id-type="doi">10.1038/srep39475</pub-id><pub-id pub-id-type="pmid">27996000</pub-id><pub-id pub-id-type="pmcid">PMC5172233</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Detienne S, Welsby I, Collignon C, Wouters S, Coccia M, Delhaye S, et al. Central Role of CD169(+) Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01. Sci Rep. 2016;6:39475.<pub-id pub-id-type="pmid">27996000</pub-id><pub-id pub-id-type="doi">10.1038/srep39475</pub-id><pub-id pub-id-type="pmcid">PMC5172233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pink</surname><given-names>JR</given-names></name><name name-style="western"><surname>Kieny</surname><given-names>M-P</given-names></name></person-group><article-title>4th Meeting on novel adjuvants currently in/close to human clinical testing</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2097</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.021</pub-id><pub-id pub-id-type="pmid">15212010</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Pink JR, Kieny M-P. 4th Meeting on novel adjuvants currently in/close to human clinical testing. Vaccine. 2004;22:2097&#8211;102.<pub-id pub-id-type="pmid">15212010</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.01.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D</given-names></name></person-group><article-title>Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants</article-title><source>Trends Pharmacological Sci</source><year>2018</year><volume>39</volume><fpage>573</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.005</pub-id><pub-id pub-id-type="pmid">29655658</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Marciani D. Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants. Trends Pharmacological Sci. 2018;39:573&#8211;85.<pub-id pub-id-type="doi">10.1016/j.tips.2018.03.005</pub-id><pub-id pub-id-type="pmid">29655658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welsby</surname><given-names>I</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S</given-names></name><name name-style="western"><surname>N&#8217;Kuli</surname><given-names>F</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Wouters</surname><given-names>S</given-names></name><name name-style="western"><surname>Bechtold</surname><given-names>V</given-names></name><etal/></person-group><article-title>Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21</article-title><source>Front Immunol</source><year>2016</year><volume>7</volume><fpage>663</fpage><pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00663</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Welsby I, Detienne S, N&#8217;Kuli F, Thomas S, Wouters S, Bechtold V, et al. Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21. Front Immunol. 2016;7:663.<pub-id pub-id-type="pmid">28105029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00663</pub-id><pub-id pub-id-type="pmcid">PMC5215313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>den Brok</surname><given-names>MH</given-names></name><name name-style="western"><surname>Nierkens</surname><given-names>S</given-names></name><name name-style="western"><surname>Wagenaars</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ruers</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Schrier</surname><given-names>CC</given-names></name><name name-style="western"><surname>Rijke</surname><given-names>EO</given-names></name><etal/></person-group><article-title>Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>737</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.080</pub-id><pub-id pub-id-type="pmid">22138178</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">den Brok MH, Nierkens S, Wagenaars JA, Ruers TJ, Schrier CC, Rijke EO, et al. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction. Vaccine. 2012;30:737&#8211;44.<pub-id pub-id-type="pmid">22138178</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>den Brok</surname><given-names>MH</given-names></name><name name-style="western"><surname>Bull</surname><given-names>C</given-names></name><name name-style="western"><surname>Wassink</surname><given-names>M</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>AM</given-names></name><name name-style="western"><surname>Wagenaars</surname><given-names>JA</given-names></name><name name-style="western"><surname>Minderman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><fpage>13324</fpage><pub-id pub-id-type="doi">10.1038/ncomms13324</pub-id><pub-id pub-id-type="pmid">27819292</pub-id><pub-id pub-id-type="pmcid">PMC5103066</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">den Brok MH, Bull C, Wassink M, de Graaf AM, Wagenaars JA, Minderman M, et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun. 2016;7:13324.<pub-id pub-id-type="pmid">27819292</pub-id><pub-id pub-id-type="doi">10.1038/ncomms13324</pub-id><pub-id pub-id-type="pmcid">PMC5103066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>K</given-names></name><name name-style="western"><surname>Garanina</surname><given-names>E</given-names></name><name name-style="western"><surname>Rizvanov</surname><given-names>A</given-names></name><name name-style="western"><surname>Khaiboullina</surname><given-names>S</given-names></name></person-group><article-title>Inflammasomes as Targets for Adjuvants</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><fpage>252</fpage><pub-id pub-id-type="doi">10.3390/pathogens9040252</pub-id><pub-id pub-id-type="pmid">32235526</pub-id><pub-id pub-id-type="pmcid">PMC7238254</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ivanov K, Garanina E, Rizvanov A, Khaiboullina S. Inflammasomes as Targets for Adjuvants. Pathogens. 2020;9:252.<pub-id pub-id-type="pmid">32235526</pub-id><pub-id pub-id-type="doi">10.3390/pathogens9040252</pub-id><pub-id pub-id-type="pmcid">PMC7238254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinke</surname><given-names>S</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>A</given-names></name><name name-style="western"><surname>Gartlan</surname><given-names>C</given-names></name><name name-style="western"><surname>Bezbradica</surname><given-names>JS</given-names></name><name name-style="western"><surname>Milicic</surname><given-names>A</given-names></name></person-group><article-title>Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><fpage>554</fpage><pub-id pub-id-type="doi">10.3390/vaccines8030554</pub-id><pub-id pub-id-type="pmid">32971761</pub-id><pub-id pub-id-type="pmcid">PMC7565252</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Reinke S, Thakur A, Gartlan C, Bezbradica JS, Milicic A. Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants. Vaccines. 2020;8:554.<pub-id pub-id-type="pmid">32971761</pub-id><pub-id pub-id-type="doi">10.3390/vaccines8030554</pub-id><pub-id pub-id-type="pmcid">PMC7565252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marty-Roix</surname><given-names>R</given-names></name><name name-style="western"><surname>Vladimer</surname><given-names>GI</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>K</given-names></name><name name-style="western"><surname>Weng</surname><given-names>D</given-names></name><name name-style="western"><surname>Buglione-Corbett</surname><given-names>R</given-names></name><name name-style="western"><surname>West</surname><given-names>K</given-names></name><etal/></person-group><article-title>Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><fpage>1123</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.683011</pub-id><pub-id pub-id-type="pmid">26555265</pub-id><pub-id pub-id-type="pmcid">PMC4714196</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Marty-Roix R, Vladimer GI, Pouliot K, Weng D, Buglione-Corbett R, West K, et al. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem. 2016;291:1123&#8211;36.<pub-id pub-id-type="pmid">26555265</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M115.683011</pub-id><pub-id pub-id-type="pmcid">PMC4714196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Kensil CR, Soltysik S, Wheeler DA, Wu JY. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria In: Waller GR, Yamasaki K, editors. Saponins Used in Traditional and Modern Medicine. New York: Plenum Press; 1996. p. 165&#8211;72.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4899-1367-8_15</pub-id><pub-id pub-id-type="pmid">8957293</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C</given-names></name><name name-style="western"><surname>Scaltreto</surname><given-names>H</given-names></name><name name-style="western"><surname>Barbon</surname><given-names>J</given-names></name><name name-style="western"><surname>Kensil</surname><given-names>CR</given-names></name></person-group><article-title>QS-21 structure/function studies: effect of acylation on adjuvant activity</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>2808</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00209-8</pub-id><pub-id pub-id-type="pmid">12034108</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine. 2002;20:2808&#8211;15.<pub-id pub-id-type="pmid">12034108</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00209-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>MM</given-names></name><name name-style="western"><surname>Damani</surname><given-names>P</given-names></name><name name-style="western"><surname>Perl</surname><given-names>NR</given-names></name><name name-style="western"><surname>Won</surname><given-names>A</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Design and synthesis of potent Quillaja saponin vaccine adjuvants</article-title><source>J Am Chem Soc</source><year>2010</year><volume>132</volume><fpage>1939</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1021/ja9082842</pub-id><pub-id pub-id-type="pmid">20088518</pub-id><pub-id pub-id-type="pmcid">PMC2820154</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Adams MM, Damani P, Perl NR, Won A, Hong F, Livingston PO, et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc. 2010;132:1939&#8211;45.<pub-id pub-id-type="pmid">20088518</pub-id><pub-id pub-id-type="doi">10.1021/ja9082842</pub-id><pub-id pub-id-type="pmcid">PMC2820154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Tejada</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>DS</given-names></name><name name-style="western"><surname>Gin</surname><given-names>DY</given-names></name></person-group><article-title>Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis</article-title><source>Acc Chem Res</source><year>2016</year><volume>49</volume><fpage>1741</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.6b00242</pub-id><pub-id pub-id-type="pmid">27568877</pub-id><pub-id pub-id-type="pmcid">PMC5032057</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Fernandez-Tejada A, Tan DS, Gin DY. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis. Acc Chem Res. 2016;49:1741&#8211;56.<pub-id pub-id-type="pmid">27568877</pub-id><pub-id pub-id-type="doi">10.1021/acs.accounts.6b00242</pub-id><pub-id pub-id-type="pmcid">PMC5032057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>OJG</given-names></name><name name-style="western"><surname>Heis</surname><given-names>F</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>C</given-names></name></person-group><article-title>Synthesis of Immunostimulatory Saponins: A Sweet Challenge for Carbohydrate Chemists</article-title><source>Carbohydr Res</source><year>2023</year><volume>530</volume><fpage>108851</fpage><pub-id pub-id-type="doi">10.1016/j.carres.2023.108851</pub-id><pub-id pub-id-type="pmid">37257206</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Marin OJG, Heis F, Gauthier C. Synthesis of Immunostimulatory Saponins: A Sweet Challenge for Carbohydrate Chemists. Carbohydr Res. 2023;530:108851.<pub-id pub-id-type="pmid">37257206</pub-id><pub-id pub-id-type="doi">10.1016/j.carres.2023.108851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>M</given-names></name><name name-style="western"><surname>Farris</surname><given-names>E</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>RV</given-names></name><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Martin</surname><given-names>T</given-names></name><etal/></person-group><article-title>Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice</article-title><source>Hum Vaccines Immunotherapeutics</source><year>2024</year><volume>20</volume><fpage>2302070</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2302070</pub-id><pub-id pub-id-type="pmcid">PMC10793695</pub-id><pub-id pub-id-type="pmid">38190806</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Ahmed M, Farris E, Swanson RV, Das S, Yang Y, Martin T, et al. Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice. Hum Vaccines Immunotherapeutics. 2024;20:2302070.<pub-id pub-id-type="doi">10.1080/21645515.2024.2302070</pub-id><pub-id pub-id-type="pmcid">PMC10793695</pub-id><pub-id pub-id-type="pmid">38190806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuentes</surname><given-names>R</given-names></name><name name-style="western"><surname>Aguinagalde</surname><given-names>L</given-names></name><name name-style="western"><surname>Pifferi</surname><given-names>C</given-names></name><name name-style="western"><surname>Plata</surname><given-names>A</given-names></name><name name-style="western"><surname>Sacristan</surname><given-names>N</given-names></name><name name-style="western"><surname>Castellana</surname><given-names>D</given-names></name><etal/></person-group><article-title>Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>865507</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.865507</pub-id><pub-id pub-id-type="pmid">35603193</pub-id><pub-id pub-id-type="pmcid">PMC9121768</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Fuentes R, Aguinagalde L, Pifferi C, Plata A, Sacristan N, Castellana D, et al. Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants. Front Immunol. 2022;13:865507.<pub-id pub-id-type="pmid">35603193</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.865507</pub-id><pub-id pub-id-type="pmcid">PMC9121768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pifferi</surname><given-names>C</given-names></name><name name-style="western"><surname>Aguinagalde</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruiz-de-Angulo</surname><given-names>A</given-names></name><name name-style="western"><surname>Sacristan</surname><given-names>N</given-names></name><name name-style="western"><surname>Baschirotto</surname><given-names>PT</given-names></name><name name-style="western"><surname>Poveda</surname><given-names>A</given-names></name><etal/></person-group><article-title>Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen</article-title><source>Chem Sci</source><year>2023</year><volume>14</volume><fpage>3501</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1039/D2SC05639A</pub-id><pub-id pub-id-type="pmid">37006677</pub-id><pub-id pub-id-type="pmcid">PMC10055764</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Pifferi C, Aguinagalde L, Ruiz-de-Angulo A, Sacristan N, Baschirotto PT, Poveda A, et al. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. Chem Sci. 2023;14:3501&#8211;13.<pub-id pub-id-type="pmid">37006677</pub-id><pub-id pub-id-type="doi">10.1039/D2SC05639A</pub-id><pub-id pub-id-type="pmcid">PMC10055764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walkowicz</surname><given-names>WE</given-names></name><name name-style="western"><surname>Fernandez-Tejada</surname><given-names>A</given-names></name><name name-style="western"><surname>George</surname><given-names>C</given-names></name><name name-style="western"><surname>Corzana</surname><given-names>F</given-names></name><name name-style="western"><surname>Jimenez-Barbero</surname><given-names>J</given-names></name><name name-style="western"><surname>Ragupathi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities</article-title><source>Chem Sci</source><year>2016</year><volume>7</volume><fpage>2371</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1039/C5SC02978C</pub-id><pub-id pub-id-type="pmid">27014435</pub-id><pub-id pub-id-type="pmcid">PMC4800320</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Walkowicz WE, Fernandez-Tejada A, George C, Corzana F, Jimenez-Barbero J, Ragupathi G, et al. Quillaja saponin variants with central glycosidic linkage modifications exhibit distinct conformations and adjuvant activities. Chem Sci. 2016;7:2371&#8211;80.<pub-id pub-id-type="pmid">27014435</pub-id><pub-id pub-id-type="doi">10.1039/C5SC02978C</pub-id><pub-id pub-id-type="pmcid">PMC4800320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>D</given-names></name><name name-style="western"><surname>Press</surname><given-names>JB</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RC</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>V</given-names></name><name name-style="western"><surname>Gundy</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>3141</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00118-3</pub-id><pub-id pub-id-type="pmid">10856794</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Marciani D, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine. 2000;18:3141&#8211;51.<pub-id pub-id-type="pmid">10856794</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00118-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RC</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Finley-Woodman</surname><given-names>K</given-names></name><name name-style="western"><surname>May</surname><given-names>RD</given-names></name></person-group><article-title>Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>3961</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00298-6</pub-id><pub-id pub-id-type="pmid">12922132</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD. Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine. 2003;21:3961&#8211;71.<pub-id pub-id-type="pmid">12922132</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00298-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleland</surname><given-names>J</given-names></name><name name-style="western"><surname>KENSIL</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lim</surname><given-names>A</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>NE</given-names></name><name name-style="western"><surname>Basa</surname><given-names>L</given-names></name><name name-style="western"><surname>Spellman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21</article-title><source>J Pharm Sci</source><year>1996</year><volume>85</volume><fpage>22</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1021/js9503136</pub-id><pub-id pub-id-type="pmid">8926578</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Cleland J, KENSIL CR, Lim A, Jacobsen NE, Basa L, Spellman M, et al. Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21. J Pharm Sci. 1996;85:22&#8211;8.<pub-id pub-id-type="pmid">8926578</pub-id><pub-id pub-id-type="doi">10.1021/js9503136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RC</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>L</given-names></name><name name-style="western"><surname>May</surname><given-names>RD</given-names></name></person-group><article-title>Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins</article-title><source>Inter Immunopharmacol</source><year>2001</year><volume>1</volume><fpage>813</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1567-5769(01)00016-9</pub-id><pub-id pub-id-type="pmid">11357894</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Inter Immunopharmacol. 2001;1:813&#8211;8.<pub-id pub-id-type="doi">10.1016/S1567-5769(01)00016-9</pub-id><pub-id pub-id-type="pmid">11357894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Ptak</surname><given-names>RG</given-names></name><name name-style="western"><surname>Voss</surname><given-names>TG</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RC</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chamblin</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine</article-title><source>Inter Immunopharmacol</source><year>2002</year><volume>2</volume><fpage>1703</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S1567-5769(02)00192-3</pub-id><pub-id pub-id-type="pmid">12469944</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Marciani DJ, Ptak RG, Voss TG, Reynolds RC, Pathak AK, Chamblin TL, et al. Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine. Inter Immunopharmacol. 2002;2:1703&#8211;11.<pub-id pub-id-type="doi">10.1016/S1567-5769(02)00192-3</pub-id><pub-id pub-id-type="pmid">12469944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marciani</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>AK</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RC</given-names></name></person-group><article-title>Quillaja saponin adjuvants: derivatives formed under sub-optimal conditions</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>3237</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00298-0</pub-id><pub-id pub-id-type="pmid">12213391</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Marciani DJ, Pathak AK, Reynolds RC. Quillaja saponin adjuvants: derivatives formed under sub-optimal conditions. Vaccine. 2002;20:3237&#8211;8.<pub-id pub-id-type="pmid">12213391</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00298-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>J</given-names></name><name name-style="western"><surname>Black</surname><given-names>KP</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name></person-group><article-title>Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><fpage>4352</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.9.4352-4359.1999</pub-id><pub-id pub-id-type="pmid">10456874</pub-id><pub-id pub-id-type="pmcid">PMC96752</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Katz J, Black KP, Michalek SM. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect Immun. 1999;67:4352&#8211;9.<pub-id pub-id-type="pmid">10456874</pub-id><pub-id pub-id-type="doi">10.1128/IAI.67.9.4352-4359.1999</pub-id><pub-id pub-id-type="pmcid">PMC96752</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>&#352;kalamera</surname><given-names>&#272;</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name></person-group><article-title>Synthesis and evaluation of a QS-17/18-based vaccine adjuvant</article-title><source>J Med Chem</source><year>2019</year><volume>62</volume><fpage>1669</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01997</pub-id><pub-id pub-id-type="pmid">30656932</pub-id><pub-id pub-id-type="pmcid">PMC6492282</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Wang P, &#352;kalamera &#272;, Sui X, Zhang P, Michalek SM. Synthesis and evaluation of a QS-17/18-based vaccine adjuvant. J Med Chem. 2019;62:1669&#8211;76.<pub-id pub-id-type="pmid">30656932</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01997</pub-id><pub-id pub-id-type="pmcid">PMC6492282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Devalankar</surname><given-names>DA</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name></person-group><article-title>Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide</article-title><source>J Org Chem</source><year>2016</year><volume>81</volume><fpage>9560</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.6b00922</pub-id><pub-id pub-id-type="pmid">27709937</pub-id><pub-id pub-id-type="pmcid">PMC6488304</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Wang P, Devalankar DA, Dai Q, Zhang P, Michalek SM. Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide. J Org Chem. 2016;81:9560&#8211;6.<pub-id pub-id-type="pmid">27709937</pub-id><pub-id pub-id-type="doi">10.1021/acs.joc.6b00922</pub-id><pub-id pub-id-type="pmcid">PMC6488304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name></person-group><article-title>Structural Effect on Adjuvanticity of Saponins</article-title><source>J Med Chem</source><year>2020</year><volume>63</volume><fpage>3290</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02063</pub-id><pub-id pub-id-type="pmid">32101001</pub-id><pub-id pub-id-type="pmcid">PMC8832471</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Wang P, Ding X, Kim H, Michalek SM, Zhang P. Structural Effect on Adjuvanticity of Saponins. J Med Chem. 2020;63:3290&#8211;7.<pub-id pub-id-type="pmid">32101001</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b02063</pub-id><pub-id pub-id-type="pmcid">PMC8832471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>&#352;kalamera</surname><given-names>&#272;</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name></person-group><article-title>Synthesis and evaluation of QS-7-based vaccine adjuvants</article-title><source>ACS Infect Dis</source><year>2019</year><volume>5</volume><fpage>974</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00039</pub-id><pub-id pub-id-type="pmid">30920199</pub-id><pub-id pub-id-type="pmcid">PMC6848976</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Wang P, &#352;kalamera &#272;, Sui X, Zhang P, Michalek SM. Synthesis and evaluation of QS-7-based vaccine adjuvants. ACS Infect Dis. 2019;5:974&#8211;81.<pub-id pub-id-type="pmid">30920199</pub-id><pub-id pub-id-type="doi">10.1021/acsinfecdis.9b00039</pub-id><pub-id pub-id-type="pmcid">PMC6848976</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name><name name-style="western"><surname>Rokutani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hara</surname><given-names>S</given-names></name><etal/></person-group><article-title>Studies on the constituents of Momordica cochinchinensis SPRENG. I. Isolation and characterization of the seed saponins, momordica saponins I and II</article-title><source>Chem Pharm Bull</source><year>1985</year><volume>33</volume><fpage>464</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1248/cpb.33.464</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Iwamoto M, Okabe H, Yamauchi T, Tanaka M, Rokutani Y, Hara S, et al. Studies on the constituents of Momordica cochinchinensis SPRENG. I. Isolation and characterization of the seed saponins, momordica saponins I and II. Chem Pharm Bull. 1985;33:464&#8211;78.<pub-id pub-id-type="doi">10.1248/cpb.33.464</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Eisenbrand</surname><given-names>G</given-names></name></person-group><source>Handbook of Chinese Medicinal Plants</source><year>2011</year><publisher-loc>Weinheim</publisher-loc><publisher-name>Wiley-VCH</publisher-name></element-citation><mixed-citation id="mc-CR92" publication-type="book">Tang W, Eisenbrand G. Handbook of Chinese Medicinal Plants. Weinheim: Wiley-VCH; 2011.</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>C</given-names></name><name name-style="western"><surname>Rajput</surname><given-names>ZI</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Enhancement of serological immune responses to foot-and-mouth disease vaccine by a supplement made of extract of cochinchina momordica seeds</article-title><source>Clin Vaccine Immunol CVI</source><year>2007</year><volume>14</volume><fpage>1634</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/CVI.00339-07</pub-id><pub-id pub-id-type="pmid">17942610</pub-id><pub-id pub-id-type="pmcid">PMC2168389</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Xiao C, Rajput ZI, Liu D, Hu S. Enhancement of serological immune responses to foot-and-mouth disease vaccine by a supplement made of extract of cochinchina momordica seeds. Clin Vaccine Immunol CVI. 2007;14:1634&#8211;9.<pub-id pub-id-type="pmid">17942610</pub-id><pub-id pub-id-type="doi">10.1128/CVI.00339-07</pub-id><pub-id pub-id-type="pmcid">PMC2168389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>JH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>ZQ</given-names></name><name name-style="western"><surname>Hu</surname><given-names>SH</given-names></name></person-group><article-title>Effect of four adjuvants on immune response to F4 fimbriae in chickens</article-title><source>Vet Immunol Immunopathol</source><year>2008</year><volume>121</volume><fpage>107</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2007.09.021</pub-id><pub-id pub-id-type="pmid">18036671</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Sun JH, Jiang ZQ, Hu SH. Effect of four adjuvants on immune response to F4 fimbriae in chickens. Vet Immunol Immunopathol. 2008;121:107&#8211;12.<pub-id pub-id-type="pmid">18036671</pub-id><pub-id pub-id-type="doi">10.1016/j.vetimm.2007.09.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>&#352;kalamera</surname><given-names>&#272;</given-names></name><name name-style="western"><surname>Michalek</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name></person-group><article-title>Vaccine adjuvants derivatized from Momordica saponins I and II</article-title><source>J Med Chem</source><year>2019</year><volume>62</volume><fpage>9976</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01511</pub-id><pub-id pub-id-type="pmid">31657920</pub-id><pub-id pub-id-type="pmcid">PMC6856410</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Wang P, Ding X, Kim H, &#352;kalamera &#272;, Michalek SM, Zhang P. Vaccine adjuvants derivatized from Momordica saponins I and II. J Med Chem. 2019;62:9976&#8211;82.<pub-id pub-id-type="pmid">31657920</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01511</pub-id><pub-id pub-id-type="pmcid">PMC6856410</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Bai</surname><given-names>D</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1079047</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1079047</pub-id><pub-id pub-id-type="pmid">36578488</pub-id><pub-id pub-id-type="pmcid">PMC9790987</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Kim H, Yu J, Bai D, Nahm MH, Wang P. Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1. Front Immunol. 2022;13:1079047.<pub-id pub-id-type="pmid">36578488</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1079047</pub-id><pub-id pub-id-type="pmcid">PMC9790987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theilacker</surname><given-names>C</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>MA</given-names></name><name name-style="western"><surname>Jodar</surname><given-names>L</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></name></person-group><article-title>PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.3390/microorganisms10010127</pub-id><pub-id pub-id-type="pmid">35056576</pub-id><pub-id pub-id-type="pmcid">PMC8778913</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Theilacker C, Fletcher MA, Jodar L, Gessner BD. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms. 2022;10:127.<pub-id pub-id-type="pmid">35056576</pub-id><pub-id pub-id-type="doi">10.3390/microorganisms10010127</pub-id><pub-id pub-id-type="pmcid">PMC8778913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>LH</given-names></name><name name-style="western"><surname>Gu</surname><given-names>XX</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name></person-group><article-title>Towards new broader spectrum pneumococcal vaccines: The future of pneumococcal disease prevention</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>112</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.3390/vaccines2010112</pub-id><pub-id pub-id-type="pmid">26344470</pub-id><pub-id pub-id-type="pmcid">PMC4494192</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Lee LH, Gu XX, Nahm MH. Towards new broader spectrum pneumococcal vaccines: The future of pneumococcal disease prevention. Vaccines. 2014;2:112&#8211;28.<pub-id pub-id-type="pmid">26344470</pub-id><pub-id pub-id-type="doi">10.3390/vaccines2010112</pub-id><pub-id pub-id-type="pmcid">PMC4494192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dransfield</surname><given-names>MT</given-names></name><name name-style="western"><surname>Harnden</surname><given-names>S</given-names></name><name name-style="western"><surname>Burton</surname><given-names>RL</given-names></name><name name-style="western"><surname>Albert</surname><given-names>RK</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>WC</given-names></name><name name-style="western"><surname>Casaburi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease</article-title><source>Clin Infect Dis</source><year>2012</year><volume>55</volume><fpage>e35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/cid/cis513</pub-id><pub-id pub-id-type="pmid">22652582</pub-id><pub-id pub-id-type="pmcid">PMC3491850</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis. 2012;55:e35&#8211;44.<pub-id pub-id-type="pmid">22652582</pub-id><pub-id pub-id-type="doi">10.1093/cid/cis513</pub-id><pub-id pub-id-type="pmcid">PMC3491850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva-Costa</surname><given-names>C</given-names></name><name name-style="western"><surname>Gomes-Silva</surname><given-names>J</given-names></name><name name-style="western"><surname>Pinho</surname><given-names>MD</given-names></name><name name-style="western"><surname>Fri&#227;es</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>M</given-names></name><name name-style="western"><surname>Melo-Cristino</surname><given-names>J</given-names></name></person-group><article-title>Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016&#8211;2019)</article-title><source>Microbiol Spectrum</source><year>2022</year><volume>10</volume><fpage>e01077</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1128/spectrum.01077-22</pub-id><pub-id pub-id-type="pmcid">PMC9431508</pub-id><pub-id pub-id-type="pmid">35862941</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Silva-Costa C, Gomes-Silva J, Pinho MD, Fri&#227;es A, Ramirez M, Melo-Cristino J. Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016&#8211;2019). Microbiol Spectrum. 2022;10:e01077&#8211;22.<pub-id pub-id-type="doi">10.1128/spectrum.01077-22</pub-id><pub-id pub-id-type="pmcid">PMC9431508</pub-id><pub-id pub-id-type="pmid">35862941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez</surname><given-names>&#194;</given-names></name><name name-style="western"><surname>Ciruela</surname><given-names>P</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia-Garcia</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Soldevila</surname><given-names>N</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7&#8211;59 months. A matched case-control study</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0183191</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0183191</pub-id><pub-id pub-id-type="pmid">28806737</pub-id><pub-id pub-id-type="pmcid">PMC5555701</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Dominguez &#194;, Ciruela P, Hernandez S, Garcia-Garcia JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7&#8211;59 months. A matched case-control study. PLoS One. 2017;12:e0183191.<pub-id pub-id-type="pmid">28806737</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0183191</pub-id><pub-id pub-id-type="pmcid">PMC5555701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horacio</surname><given-names>AN</given-names></name><name name-style="western"><surname>Silva-Costa</surname><given-names>C</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>JP</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>M</given-names></name><name name-style="western"><surname>Melo-Cristino</surname><given-names>J</given-names></name></person-group><article-title>Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in portugal (2012&#8211;2014) despite continued reductions in other 13-valent conjugate vaccine serotypes</article-title><source>Front Microbiol</source><year>2016</year><volume>14</volume><fpage>1616</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2016.01616</pub-id><pub-id pub-id-type="pmcid">PMC5064670</pub-id><pub-id pub-id-type="pmid">27790208</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Horacio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in portugal (2012&#8211;2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol. 2016;14:1616.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2016.01616</pub-id><pub-id pub-id-type="pmcid">PMC5064670</pub-id><pub-id pub-id-type="pmid">27790208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name><name name-style="western"><surname>LaFon</surname><given-names>D</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name></person-group><article-title>Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease</article-title><source>Infect Chemother</source><year>2016</year><volume>48</volume><fpage>257</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.3947/ic.2016.48.4.257</pub-id><pub-id pub-id-type="pmid">28032483</pub-id><pub-id pub-id-type="pmcid">PMC5204004</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Kim YK, LaFon D, Nahm MH. Indirect effects of pneumococcal conjugate vaccines in national immunization programs for children on adult pneumococcal disease. Infect Chemother. 2016;48:257&#8211;66.<pub-id pub-id-type="pmid">28032483</pub-id><pub-id pub-id-type="doi">10.3947/ic.2016.48.4.257</pub-id><pub-id pub-id-type="pmcid">PMC5204004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>G</given-names></name><name name-style="western"><surname>Garcia-Garcia</surname><given-names>S</given-names></name><name name-style="western"><surname>Lanaspa</surname><given-names>M</given-names></name><name name-style="western"><surname>Ciruela</surname><given-names>P</given-names></name><name name-style="western"><surname>Esteva</surname><given-names>C</given-names></name><name name-style="western"><surname>Fernandez de Sevilla</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain</article-title><source>PloS One</source><year>2020</year><volume>15</volume><fpage>e0228612</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0228612</pub-id><pub-id pub-id-type="pmid">32027715</pub-id><pub-id pub-id-type="pmcid">PMC7004304</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Ludwig G, Garcia-Garcia S, Lanaspa M, Ciruela P, Esteva C, Fernandez de Sevilla M, et al. Serotype and clonal distribution dynamics of invasive pneumococcal strains after PCV13 introduction (2011-2016): Surveillance data from 23 sites in Catalonia, Spain. PloS One. 2020;15:e0228612.<pub-id pub-id-type="pmid">32027715</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0228612</pub-id><pub-id pub-id-type="pmcid">PMC7004304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Levy</surname><given-names>C</given-names></name><name name-style="western"><surname>Ouldali</surname><given-names>N</given-names></name><name name-style="western"><surname>Goldrey</surname><given-names>M</given-names></name><name name-style="western"><surname>Bechet</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonacorsi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><fpage>1453</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa917</pub-id><pub-id pub-id-type="pmid">32804200</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Cohen R, Levy C, Ouldali N, Goldrey M, Bechet S, Bonacorsi S, et al. Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation. Clin Infect Dis. 2021;72:1453&#8211;6.<pub-id pub-id-type="pmid">32804200</pub-id><pub-id pub-id-type="doi">10.1093/cid/ciaa917</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><mixed-citation publication-type="other">Corcoran M, Vickers I, Fitzgerald M, Mereckiene J, Murchan S, Cotter S. The persistence of serotype 19A - Despite the introduction of PCV13 vaccine. UK: Glasgow; 2016.</mixed-citation></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mungall</surname><given-names>BA</given-names></name><name name-style="western"><surname>Hoet</surname><given-names>B</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>JN</given-names></name><name name-style="western"><surname>Soumahoro</surname><given-names>L</given-names></name></person-group><article-title>A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children</article-title><source>Expert Rev Vaccines</source><year>2022</year><volume>21</volume><fpage>201</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2012455</pub-id><pub-id pub-id-type="pmid">34882050</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Mungall BA, Hoet B, Guevara JN, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21:201&#8211;14.<pub-id pub-id-type="pmid">34882050</pub-id><pub-id pub-id-type="doi">10.1080/14760584.2022.2012455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaFon</surname><given-names>DC</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name></person-group><article-title>Measuring quantity and function of pneumococcal antibodies in immunoglobulin products</article-title><source>Transfusion</source><year>2018</year><volume>58</volume><fpage>3114</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1111/trf.15015</pub-id><pub-id pub-id-type="pmid">30536435</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">LaFon DC, Nahm MH. Measuring quantity and function of pneumococcal antibodies in immunoglobulin products. Transfusion. 2018;58:3114&#8211;20.<pub-id pub-id-type="pmid">30536435</pub-id><pub-id pub-id-type="doi">10.1111/trf.15015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burton</surname><given-names>RL</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name></person-group><article-title>Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20</article-title><source>Clin Vaccine Immunol CVI</source><year>2012</year><volume>19</volume><fpage>835</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1128/CVI.00086-12</pub-id><pub-id pub-id-type="pmid">22518015</pub-id><pub-id pub-id-type="pmcid">PMC3370448</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol CVI. 2012;19:835&#8211;41.<pub-id pub-id-type="pmid">22518015</pub-id><pub-id pub-id-type="doi">10.1128/CVI.00086-12</pub-id><pub-id pub-id-type="pmcid">PMC3370448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>JY</given-names></name><name name-style="western"><surname>Moseley</surname><given-names>MA</given-names></name><name name-style="western"><surname>Burton</surname><given-names>RL</given-names></name><name name-style="western"><surname>Nahm</surname><given-names>MH</given-names></name></person-group><article-title>Pneumococcal vaccine and opsonic pneumococcal antibody</article-title><source>J Infect Chemother</source><year>2013</year><volume>19</volume><fpage>412</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s10156-013-0601-1</pub-id><pub-id pub-id-type="pmid">23657429</pub-id><pub-id pub-id-type="pmcid">PMC3692352</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Song JY, Moseley MA, Burton RL, Nahm MH. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother. 2013;19:412&#8211;25.<pub-id pub-id-type="pmid">23657429</pub-id><pub-id pub-id-type="doi">10.1007/s10156-013-0601-1</pub-id><pub-id pub-id-type="pmcid">PMC3692352</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatnagar</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>BR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Gill</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Adjuvant effects of a new saponin analog VSA-1 on enhancing homologous and heterosubtypic protection by influenza virus vaccination</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><fpage>1383</fpage><pub-id pub-id-type="doi">10.3390/vaccines10091383</pub-id><pub-id pub-id-type="pmid">36146461</pub-id><pub-id pub-id-type="pmcid">PMC9501088</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Bhatnagar N, Kim K-H, Subbiah J, Park BR, Wang P, Gill HS, et al. Adjuvant effects of a new saponin analog VSA-1 on enhancing homologous and heterosubtypic protection by influenza virus vaccination. Vaccines. 2022;10:1383.<pub-id pub-id-type="pmid">36146461</pub-id><pub-id pub-id-type="doi">10.3390/vaccines10091383</pub-id><pub-id pub-id-type="pmcid">PMC9501088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iuliano</surname><given-names>AD</given-names></name><name name-style="western"><surname>Roguski</surname><given-names>KM</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HH</given-names></name><name name-style="western"><surname>Muscatello</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Palekar</surname><given-names>R</given-names></name><name name-style="western"><surname>Tempia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Estimates of global seasonal influenza-associated respiratory mortality: a modelling study</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1285</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmid">29248255</pub-id><pub-id pub-id-type="pmcid">PMC5935243</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285&#8211;300.<pub-id pub-id-type="pmid">29248255</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmcid">PMC5935243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Bian</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><etal/></person-group><article-title>The next major emergent infectious disease: reflections on vaccine emergency development strategies</article-title><source>Expert Rev Vaccines</source><year>2022</year><volume>21</volume><fpage>471</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2027240</pub-id><pub-id pub-id-type="pmid">35080441</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Bai Y, Wang Q, Liu M, Bian L, Liu J, Gao F, et al. The next major emergent infectious disease: reflections on vaccine emergency development strategies. Expert Rev Vaccines. 2022;21:471&#8211;81.<pub-id pub-id-type="pmid">35080441</pub-id><pub-id pub-id-type="doi">10.1080/14760584.2022.2027240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wille</surname><given-names>M</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name></person-group><article-title>The Ecology and Evolution of Influenza Viruses</article-title><source>Cold Spring Harb Perspect Med</source><year>2020</year><volume>10</volume><fpage>a038489</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a038489</pub-id><pub-id pub-id-type="pmid">31871237</pub-id><pub-id pub-id-type="pmcid">PMC7328453</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Wille M, Holmes EC. The Ecology and Evolution of Influenza Viruses. Cold Spring Harb Perspect Med. 2020;10:a038489.<pub-id pub-id-type="pmid">31871237</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a038489</pub-id><pub-id pub-id-type="pmcid">PMC7328453</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Bai</surname><given-names>D</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Franks</surname><given-names>ML</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Structure&#8722;Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants</article-title><source>J Med Chem</source><year>2022</year><volume>65</volume><fpage>14589</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01087</pub-id><pub-id pub-id-type="pmid">36318612</pub-id><pub-id pub-id-type="pmcid">PMC10202417</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Kim H, Bai D, Ghosh S, Franks ML, Wang X, Yan C, et al. Structure&#8722;Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants. J Med Chem. 2022;65:14589&#8211;98.<pub-id pub-id-type="pmid">36318612</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01087</pub-id><pub-id pub-id-type="pmcid">PMC10202417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leavenworth</surname><given-names>J</given-names></name><name name-style="western"><surname>Verbinnen</surname><given-names>B</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>H</given-names></name></person-group><article-title>A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells</article-title><source>Nat Immunol</source><year>2015</year><volume>16</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/ni.3050</pub-id><pub-id pub-id-type="pmid">25436971</pub-id><pub-id pub-id-type="pmcid">PMC4405167</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Leavenworth J, Verbinnen B, Yin J, Huang H, Cantor H. A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol. 2015;16:96&#8211;106.<pub-id pub-id-type="pmid">25436971</pub-id><pub-id pub-id-type="doi">10.1038/ni.3050</pub-id><pub-id pub-id-type="pmcid">PMC4405167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>E</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>H</given-names></name><name name-style="western"><surname>Leavenworth</surname><given-names>JW</given-names></name></person-group><article-title>Chromatin remodeling by the NuRD complex regulates development of follicular helper and regulatory T cells</article-title><source>Proc Natl Acad Sci USA</source><year>2018</year><volume>115</volume><fpage>6780</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1805239115</pub-id><pub-id pub-id-type="pmid">29891681</pub-id><pub-id pub-id-type="pmcid">PMC6042103</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Shen E, Wang Q, Rabe H, Liu W, Cantor H, Leavenworth JW. Chromatin remodeling by the NuRD complex regulates development of follicular helper and regulatory T cells. Proc Natl Acad Sci USA. 2018;115:6780&#8211;5.<pub-id pub-id-type="pmid">29891681</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1805239115</pub-id><pub-id pub-id-type="pmcid">PMC6042103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>E</given-names></name><name name-style="western"><surname>Rabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Control of germinal center localization and lineage stability of follicular regulatory T cells by the Blimp1 transcription factor</article-title><source>Cell Rep</source><year>2019</year><volume>29</volume><fpage>1848</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.012</pub-id><pub-id pub-id-type="pmid">31722202</pub-id><pub-id pub-id-type="pmcid">PMC6897316</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Shen E, Rabe H, Luo L, Wang L, Wang Q, Yin J, et al. Control of germinal center localization and lineage stability of follicular regulatory T cells by the Blimp1 transcription factor. Cell Rep. 2019;29:1848&#8211;61.<pub-id pub-id-type="pmid">31722202</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.012</pub-id><pub-id pub-id-type="pmcid">PMC6897316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>ML</given-names></name><name name-style="western"><surname>Pope</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Leavenworth</surname><given-names>JD</given-names></name><name name-style="western"><surname>Raman</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dysregulated follicular regulatory T cells and antibody responses exacerbate experimental autoimmune encephalomyelitis</article-title><source>J Neuroinflammation</source><year>2021</year><volume>18</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1186/s12974-021-02076-4</pub-id><pub-id pub-id-type="pmid">33468194</pub-id><pub-id pub-id-type="pmcid">PMC7814531</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Luo L, Hu X, Dixon ML, Pope BJ, Leavenworth JD, Raman C, et al. Dysregulated follicular regulatory T cells and antibody responses exacerbate experimental autoimmune encephalomyelitis. J Neuroinflammation. 2021;18:27.<pub-id pub-id-type="pmid">33468194</pub-id><pub-id pub-id-type="doi">10.1186/s12974-021-02076-4</pub-id><pub-id pub-id-type="pmcid">PMC7814531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dini</surname><given-names>I</given-names></name><name name-style="western"><surname>Schettino</surname><given-names>O</given-names></name><name name-style="western"><surname>Simioli</surname><given-names>T</given-names></name><name name-style="western"><surname>Dini</surname><given-names>A</given-names></name></person-group><article-title>Studies on the constituents of Chenopodium quinoa seeds: isolation and characterization of new triterpene saponins</article-title><source>J Agric Food Chem</source><year>2001</year><volume>49</volume><fpage>741</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1021/jf000971y</pub-id><pub-id pub-id-type="pmid">11262022</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Dini I, Schettino O, Simioli T, Dini A. Studies on the constituents of Chenopodium quinoa seeds: isolation and characterization of new triterpene saponins. J Agric Food Chem. 2001;49:741&#8211;6.<pub-id pub-id-type="pmid">11262022</pub-id><pub-id pub-id-type="doi">10.1021/jf000971y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparg</surname><given-names>SG</given-names></name><name name-style="western"><surname>Light</surname><given-names>ME</given-names></name><name name-style="western"><surname>van Staden</surname><given-names>J</given-names></name></person-group><article-title>Biological activities and distribution of plant saponins</article-title><source>J Ethnopharmacol</source><year>2004</year><volume>94</volume><fpage>219</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2004.05.016</pub-id><pub-id pub-id-type="pmid">15325725</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol. 2004;94:219&#8211;43.<pub-id pub-id-type="pmid">15325725</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2004.05.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Potentials of saponins-based adjuvants for nasal vaccines</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1153042</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1153042</pub-id><pub-id pub-id-type="pmid">37020548</pub-id><pub-id pub-id-type="pmcid">PMC10067588</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Chen K, Wang N, Zhang X, Wang M, Liu Y, Shi Y. Potentials of saponins-based adjuvants for nasal vaccines. Front Immunol. 2023;14:1153042.<pub-id pub-id-type="pmid">37020548</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1153042</pub-id><pub-id pub-id-type="pmcid">PMC10067588</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mieres-Castro</surname><given-names>D</given-names></name><name name-style="western"><surname>Mora-Poblete</surname><given-names>F</given-names></name></person-group><article-title>Saponins: Research Progress and Their Potential Role in the Post-COVID-19 Pandemic Era</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>348</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020348</pub-id><pub-id pub-id-type="pmid">36839670</pub-id><pub-id pub-id-type="pmcid">PMC9964560</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Mieres-Castro D, Mora-Poblete F. Saponins: Research Progress and Their Potential Role in the Post-COVID-19 Pandemic Era. Pharmaceutics. 2023;15:348.<pub-id pub-id-type="pmid">36839670</pub-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020348</pub-id><pub-id pub-id-type="pmcid">PMC9964560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Potential Immunoregulatory Mechanism of Plant Saponins: A Review</article-title><source>Molecules</source><year>2023</year><volume>29</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.3390/molecules29010113</pub-id><pub-id pub-id-type="pmid">38202696</pub-id><pub-id pub-id-type="pmcid">PMC10780299</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Shen L, Luo H, Fan L, Tian X, Tang A, Wu X, et al. Potential Immunoregulatory Mechanism of Plant Saponins: A Review. Molecules. 2023;29:113.<pub-id pub-id-type="pmid">38202696</pub-id><pub-id pub-id-type="doi">10.3390/molecules29010113</pub-id><pub-id pub-id-type="pmcid">PMC10780299</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krivorutchenko</surname><given-names>YL</given-names></name><name name-style="western"><surname>Andronovskaja</surname><given-names>IB</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J</given-names></name><name name-style="western"><surname>Krivoshein</surname><given-names>YS</given-names></name><name name-style="western"><surname>Ljungdahl-Stahle</surname><given-names>E</given-names></name><name name-style="western"><surname>Pertel</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>1479</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00065-0</pub-id><pub-id pub-id-type="pmid">9302764</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Krivorutchenko YL, Andronovskaja IB, Hinkula J, Krivoshein YS, Ljungdahl-Stahle E, Pertel SS, et al. Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro. Vaccine. 1997;15:1479&#8211;86.<pub-id pub-id-type="pmid">9302764</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00065-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Bao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>51</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.030</pub-id><pub-id pub-id-type="pmid">18973783</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Song X, Bao S, Wu L, Hu S. Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice. Vaccine. 2009;27:51&#8211;5.<pub-id pub-id-type="pmid">18973783</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><name name-style="western"><surname>Pei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S</given-names></name></person-group><article-title>Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice</article-title><source>Int Immunopharmacol</source><year>2014</year><volume>20</volume><fpage>283</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2014.03.008</pub-id><pub-id pub-id-type="pmid">24680943</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Su X, Pei Z, Hu S. Ginsenoside Re as an adjuvant to enhance the immune response to the inactivated rabies virus vaccine in mice. Int Immunopharmacol. 2014;20:283&#8211;9.<pub-id pub-id-type="pmid">24680943</pub-id><pub-id pub-id-type="doi">10.1016/j.intimp.2014.03.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Su</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>F</given-names></name><etal/></person-group><article-title>Rapeseed oil and ginseng saponins work synergistically to enhance Th1 and Th2 immune responses induced by the foot-and-mouth disease vaccine</article-title><source>Clin Vaccine Immunol CVI</source><year>2014</year><volume>21</volume><fpage>1113</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/CVI.00127-14</pub-id><pub-id pub-id-type="pmid">24920601</pub-id><pub-id pub-id-type="pmcid">PMC4135922</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Zhang C, Wang Y, Wang M, Su X, Lu Y, Su F, et al. Rapeseed oil and ginseng saponins work synergistically to enhance Th1 and Th2 immune responses induced by the foot-and-mouth disease vaccine. Clin Vaccine Immunol CVI. 2014;21:1113&#8211;9.<pub-id pub-id-type="pmid">24920601</pub-id><pub-id pub-id-type="doi">10.1128/CVI.00127-14</pub-id><pub-id pub-id-type="pmcid">PMC4135922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>An aluminium adjuvant compound with ginseng stem leaf saponins enhances the potency of inactivated Pseudomonas plecoglossicida vaccine in large yellow croaker (Larimichthys crocea)</article-title><source>Fish Shellfish Immunol</source><year>2024</year><volume>144</volume><fpage>109243</fpage><pub-id pub-id-type="doi">10.1016/j.fsi.2023.109243</pub-id><pub-id pub-id-type="pmid">37995892</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Sun F, Wu Y, Zhang Y, Liu Q, Wang Q, Liu X. An aluminium adjuvant compound with ginseng stem leaf saponins enhances the potency of inactivated Pseudomonas plecoglossicida vaccine in large yellow croaker (Larimichthys crocea). Fish Shellfish Immunol. 2024;144:109243.<pub-id pub-id-type="pmid">37995892</pub-id><pub-id pub-id-type="doi">10.1016/j.fsi.2023.109243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>F</given-names></name><name name-style="western"><surname>Ye</surname><given-names>YP</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name></person-group><article-title>Haemolytic activity and adjuvant effect of notoginsenoside K from the roots of Panax notoginseng</article-title><source>Chem Biodivers</source><year>2006</year><volume>3</volume><fpage>1144</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/cbdv.200690116</pub-id><pub-id pub-id-type="pmid">17193229</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Qin F, Ye YP, Sun HX. Haemolytic activity and adjuvant effect of notoginsenoside K from the roots of Panax notoginseng. Chem Biodivers. 2006;3:1144&#8211;52.<pub-id pub-id-type="pmid">17193229</pub-id><pub-id pub-id-type="doi">10.1002/cbdv.200690116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name><name name-style="western"><surname>Qin</surname><given-names>F</given-names></name><name name-style="western"><surname>Ye</surname><given-names>YP</given-names></name></person-group><article-title>Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>5533</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.07.036</pub-id><pub-id pub-id-type="pmid">16115706</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Sun HX, Qin F, Ye YP. Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng. Vaccine. 2005;23:5533&#8211;42.<pub-id pub-id-type="pmid">16115706</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.07.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>N</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>VK</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>P</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DK</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Darokar</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Adjuvant effect of Asparagus racemosus Willd. derived saponins in antibody production, allergic response and pro-inflammatory cytokine modulation</article-title><source>Biomed Pharmacother</source><year>2017</year><volume>86</volume><fpage>555</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.087</pub-id><pub-id pub-id-type="pmid">28024292</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Tiwari N, Gupta VK, Pandey P, Patel DK, Banerjee S, Darokar MP, et al. Adjuvant effect of Asparagus racemosus Willd. derived saponins in antibody production, allergic response and pro-inflammatory cytokine modulation. Biomed Pharmacother. 2017;86:555&#8211;61.<pub-id pub-id-type="pmid">28024292</pub-id><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.087</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautam</surname><given-names>M</given-names></name><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name><name name-style="western"><surname>Bani</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>A</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D</given-names></name><etal/></person-group><article-title>Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: implications for immunoadjuvant potential</article-title><source>J Ethnopharmacol</source><year>2009</year><volume>121</volume><fpage>241</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2008.10.028</pub-id><pub-id pub-id-type="pmid">19038322</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Gautam M, Saha S, Bani S, Kaul A, Mishra S, Patil D, et al. Immunomodulatory activity of Asparagus racemosus on systemic Th1/Th2 immunity: implications for immunoadjuvant potential. J Ethnopharmacol. 2009;121:241&#8211;7.<pub-id pub-id-type="pmid">19038322</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2008.10.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D</given-names></name><etal/></person-group><article-title>A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1154836</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1154836</pub-id><pub-id pub-id-type="pmid">37415983</pub-id><pub-id pub-id-type="pmcid">PMC10319991</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Luo X, Song Z, Zeng X, Ye Y, Zheng H, Cai D, et al. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect. Front Immunol. 2023;14:1154836.<pub-id pub-id-type="pmid">37415983</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1154836</pub-id><pub-id pub-id-type="pmcid">PMC10319991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palanisamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Singh</surname><given-names>PP</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>U</given-names></name><name name-style="western"><surname>Patil</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mal</surname><given-names>G</given-names></name><etal/></person-group><article-title>Shatavarin-IV saponin adjuvant elicits IgG and IgG2b responses against Staphylococcus aureus bacterin in a murine model</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><fpage>e15339</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e15339</pub-id><pub-id pub-id-type="pmid">37123899</pub-id><pub-id pub-id-type="pmcid">PMC10133762</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Palanisamy A, Sharma R, Singh PP, Sharma U, Patil RD, Mal G, et al. Shatavarin-IV saponin adjuvant elicits IgG and IgG2b responses against Staphylococcus aureus bacterin in a murine model. Heliyon. 2023;9:e15339.<pub-id pub-id-type="pmid">37123899</pub-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e15339</pub-id><pub-id pub-id-type="pmcid">PMC10133762</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubio-Moraga</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Gerwig</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Castro-D&#237;az</surname><given-names>N</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>ML</given-names></name><name name-style="western"><surname>Escribano</surname><given-names>J</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J-A</given-names></name><etal/></person-group><article-title>Triterpenoid saponins from corms of Crocus sativus: Localization, extraction and characterization</article-title><source>Industrial Crops Products</source><year>2011</year><volume>34</volume><fpage>1401</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2011.04.013</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Rubio-Moraga &#193;, Gerwig GJ, Castro-D&#237;az N, Jimeno ML, Escribano J, Fern&#225;ndez J-A, et al. Triterpenoid saponins from corms of Crocus sativus: Localization, extraction and characterization. Industrial Crops Products. 2011;34:1401&#8211;9.<pub-id pub-id-type="doi">10.1016/j.indcrop.2011.04.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Jung</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name></person-group><article-title>An 8-week randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of red Platycodon grandiflorus root extract on enhancement of immune function</article-title><source>Phytomedicine</source><year>2021</year><volume>93</volume><fpage>153811</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2021.153811</pub-id><pub-id pub-id-type="pmid">34735908</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Park EJ, Jung AJ, Lee SH, Kang SK, Lee HJ. An 8-week randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of red Platycodon grandiflorus root extract on enhancement of immune function. Phytomedicine. 2021;93:153811.<pub-id pub-id-type="pmid">34735908</pub-id><pub-id pub-id-type="doi">10.1016/j.phymed.2021.153811</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses</article-title><source>Int Immunopharmacol</source><year>2008</year><volume>8</volume><fpage>1143</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2008.04.006</pub-id><pub-id pub-id-type="pmid">18550019</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Xie Y, Deng W, Sun H, Li D. Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses. Int Immunopharmacol. 2008;8:1143&#8211;50.<pub-id pub-id-type="pmid">18550019</pub-id><pub-id pub-id-type="doi">10.1016/j.intimp.2008.04.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3937</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.061</pub-id><pub-id pub-id-type="pmid">18547688</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Xie Y, Pan H, Sun H, Li D. A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum. Vaccine. 2008;26:3937&#8211;45.<pub-id pub-id-type="pmid">18547688</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name></person-group><article-title>Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3432</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.014</pub-id><pub-id pub-id-type="pmid">16519972</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Sun HX. Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice. Vaccine. 2006;24:3432&#8211;9.<pub-id pub-id-type="pmid">16519972</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ushio</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abe</surname><given-names>H</given-names></name></person-group><article-title>Effect of saikosaponin on the immune responses in mice</article-title><source>Int J Immunopharm</source><year>1991</year><volume>13</volume><fpage>501</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0192-0561(91)90069-J</pub-id><pub-id pub-id-type="pmid">1783462</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Ushio Y, Oda Y, Abe H. Effect of saikosaponin on the immune responses in mice. Int J Immunopharm. 1991;13:501&#8211;8.<pub-id pub-id-type="doi">10.1016/0192-0561(91)90069-J</pub-id><pub-id pub-id-type="pmid">1783462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verza</surname><given-names>SG</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>F</given-names></name><name name-style="western"><surname>Cibulski</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F</given-names></name><name name-style="western"><surname>Gosmann</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immunoadjuvant activity, toxicity assays, and determination by UPLC/Q-TOF-MS of triterpenic saponins from Chenopodium quinoa seeds</article-title><source>J Agric Food Chem</source><year>2012</year><volume>60</volume><fpage>3113</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1021/jf205010c</pub-id><pub-id pub-id-type="pmid">22394456</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Verza SG, Silveira F, Cibulski S, Kaiser S, Ferreira F, Gosmann G, et al. Immunoadjuvant activity, toxicity assays, and determination by UPLC/Q-TOF-MS of triterpenic saponins from Chenopodium quinoa seeds. J Agric Food Chem. 2012;60:3113&#8211;8.<pub-id pub-id-type="pmid">22394456</pub-id><pub-id pub-id-type="doi">10.1021/jf205010c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatuntseva</surname><given-names>EA</given-names></name><name name-style="western"><surname>Men&#8217;shov</surname><given-names>VM</given-names></name><name name-style="western"><surname>Shashkov</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tsvetkov</surname><given-names>YE</given-names></name><name name-style="western"><surname>Stepanenko</surname><given-names>RN</given-names></name><name name-style="western"><surname>Vlasenko</surname><given-names>RY</given-names></name><etal/></person-group><article-title>Triterpenoid saponins from the roots of Acanthophyllum gypsophiloides Regel</article-title><source>Beilstein J Org Chem</source><year>2012</year><volume>8</volume><fpage>763</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3762/bjoc.8.87</pub-id><pub-id pub-id-type="pmid">23015825</pub-id><pub-id pub-id-type="pmcid">PMC3388865</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Khatuntseva EA, Men&#8217;shov VM, Shashkov AS, Tsvetkov YE, Stepanenko RN, Vlasenko RY, et al. Triterpenoid saponins from the roots of Acanthophyllum gypsophiloides Regel. Beilstein J Org Chem. 2012;8:763&#8211;75.<pub-id pub-id-type="pmid">23015825</pub-id><pub-id pub-id-type="doi">10.3762/bjoc.8.87</pub-id><pub-id pub-id-type="pmcid">PMC3388865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M-A</given-names></name><name name-style="western"><surname>Hanquet</surname><given-names>B</given-names></name><name name-style="western"><surname>Rustaiyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H</given-names></name></person-group><article-title>Squarroside A, A biologically active triterpene saponin from Acanthophyllum Squarrosum</article-title><source>Phytochem</source><year>1993</year><volume>34</volume><fpage>489</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0031-9422(93)80036-R</pub-id><pub-id pub-id-type="pmid">7764142</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Lacaille-Dubois M-A, Hanquet B, Rustaiyan A, Wagner H. Squarroside A, A biologically active triterpene saponin from Acanthophyllum Squarrosum. Phytochem. 1993;34:489&#8211;95.<pub-id pub-id-type="doi">10.1016/0031-9422(93)80036-R</pub-id><pub-id pub-id-type="pmid">7764142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaidi</surname><given-names>G</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Rustaiyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Laurens</surname><given-names>V</given-names></name><name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M-A</given-names></name></person-group><article-title>Two New Biologically Active Triterpene Saponins from Acanthophyllum squarrosum</article-title><source>J Nat Prod</source><year>2000</year><volume>63</volume><fpage>1497</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1021/np000212+</pub-id><pub-id pub-id-type="pmid">11087591</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Gaidi G, Miyamoto T, Rustaiyan A, Laurens V, Lacaille-Dubois M-A. Two New Biologically Active Triterpene Saponins from Acanthophyllum squarrosum. J Nat Prod. 2000;63:1497&#8211;502.<pub-id pub-id-type="pmid">11087591</pub-id><pub-id pub-id-type="doi">10.1021/np000212+</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turmagambetova</surname><given-names>AS</given-names></name><name name-style="western"><surname>Alexyuk</surname><given-names>PG</given-names></name><name name-style="western"><surname>Bogoyavlenskiy</surname><given-names>AP</given-names></name><name name-style="western"><surname>Zaitseva</surname><given-names>IA</given-names></name><name name-style="western"><surname>Omirtaeva</surname><given-names>ES</given-names></name><name name-style="western"><surname>Alexyuk</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Adjuvant activity of saponins from Kazakhstani plants on the immune responses to subunit influenza vaccine</article-title><source>Arch Virol</source><year>2017</year><volume>162</volume><fpage>3817</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s00705-017-3560-5</pub-id><pub-id pub-id-type="pmid">28936557</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Turmagambetova AS, Alexyuk PG, Bogoyavlenskiy AP, Zaitseva IA, Omirtaeva ES, Alexyuk MS, et al. Adjuvant activity of saponins from Kazakhstani plants on the immune responses to subunit influenza vaccine. Arch Virol. 2017;162:3817&#8211;26.<pub-id pub-id-type="pmid">28936557</pub-id><pub-id pub-id-type="doi">10.1007/s00705-017-3560-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J-G</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Takaya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>M</given-names></name></person-group><article-title>Two New Monodesmosidic Triterpene Saponins from Gypsophila oldhamiana</article-title><source>Chem Pharm Bull</source><year>2006</year><volume>54</volume><fpage>1200</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1248/cpb.54.1200</pub-id><pub-id pub-id-type="pmid">16880670</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Luo J-G, Kong L-Y, Takaya Y, Niwa M. Two New Monodesmosidic Triterpene Saponins from Gypsophila oldhamiana. Chem Pharm Bull. 2006;54:1200&#8211;2.<pub-id pub-id-type="doi">10.1248/cpb.54.1200</pub-id><pub-id pub-id-type="pmid">16880670</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacaille-Dubois</surname><given-names>M-A</given-names></name><name name-style="western"><surname>Hanquet</surname><given-names>B</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z-H</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z-C</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H</given-names></name></person-group><article-title>Jenisseensosides C and D, biologically active acylated triterpene saponins from Silene Jenisseensis</article-title><source>Phytochem</source><year>1997</year><volume>45</volume><fpage>985</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(97)00087-3</pub-id><pub-id pub-id-type="pmid">9264608</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Lacaille-Dubois M-A, Hanquet B, Cui Z-H, Lou Z-C, Wagner H. Jenisseensosides C and D, biologically active acylated triterpene saponins from Silene Jenisseensis. Phytochem. 1997;45:985&#8211;90.<pub-id pub-id-type="doi">10.1016/S0031-9422(97)00087-3</pub-id><pub-id pub-id-type="pmid">9264608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>Adjuvant activity of tubeimosides by mediating the local immune microenvironment</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1108244</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1108244</pub-id><pub-id pub-id-type="pmid">36845089</pub-id><pub-id pub-id-type="pmcid">PMC9950507</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Han Z, Jin J, Chen X, He Y, Sun H. Adjuvant activity of tubeimosides by mediating the local immune microenvironment. Front Immunol. 2023;14:1108244.<pub-id pub-id-type="pmid">36845089</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1108244</pub-id><pub-id pub-id-type="pmcid">PMC9950507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name></person-group><article-title>Haemolytic activities and adjuvant effect of Gynostemma pentaphyllum saponins on the immune responses to ovalbumin in mice</article-title><source>Phytother Res</source><year>2005</year><volume>19</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1002/ptr.1754</pub-id><pub-id pub-id-type="pmid">16261522</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Sun H, Zheng Q. Haemolytic activities and adjuvant effect of Gynostemma pentaphyllum saponins on the immune responses to ovalbumin in mice. Phytother Res. 2005;19:895&#8211;900.<pub-id pub-id-type="pmid">16261522</pub-id><pub-id pub-id-type="doi">10.1002/ptr.1754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarikahya</surname><given-names>NB</given-names></name><name name-style="western"><surname>Nalbantsoy</surname><given-names>A</given-names></name><name name-style="western"><surname>Top</surname><given-names>H</given-names></name><name name-style="western"><surname>Gokturk</surname><given-names>RS</given-names></name><name name-style="western"><surname>Sumbul</surname><given-names>H</given-names></name><name name-style="western"><surname>Kirmizigul</surname><given-names>S</given-names></name></person-group><article-title>Immunomodulatory, hemolytic and cytotoxic activity potentials of triterpenoid saponins from eight Cephalaria species</article-title><source>Phytomedicine</source><year>2018</year><volume>38</volume><fpage>135</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2017.11.009</pub-id><pub-id pub-id-type="pmid">29425646</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Sarikahya NB, Nalbantsoy A, Top H, Gokturk RS, Sumbul H, Kirmizigul S. Immunomodulatory, hemolytic and cytotoxic activity potentials of triterpenoid saponins from eight Cephalaria species. Phytomedicine. 2018;38:135&#8211;44.<pub-id pub-id-type="pmid">29425646</pub-id><pub-id pub-id-type="doi">10.1016/j.phymed.2017.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abaci</surname><given-names>H</given-names></name><name name-style="western"><surname>Akagac</surname><given-names>G</given-names></name><name name-style="western"><surname>Nalbantsoy</surname><given-names>A</given-names></name><name name-style="western"><surname>Sarikahya</surname><given-names>NB</given-names></name></person-group><article-title>A hederagenin-type triterpene saponin, sumbulianoside a from Cephalaria sumbuliana and its potent immunomodulatory activity against seasonal flu virus H3N2</article-title><source>Natural Product Res</source><year>2022</year><volume>36</volume><fpage>2495</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1080/14786419.2021.1910691</pub-id><pub-id pub-id-type="pmid">33843360</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Abaci H, Akagac G, Nalbantsoy A, Sarikahya NB. A hederagenin-type triterpene saponin, sumbulianoside a from Cephalaria sumbuliana and its potent immunomodulatory activity against seasonal flu virus H3N2. Natural Product Res. 2022;36:2495&#8211;505.<pub-id pub-id-type="doi">10.1080/14786419.2021.1910691</pub-id><pub-id pub-id-type="pmid">33843360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>J</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>N</given-names></name><name name-style="western"><surname>Seo</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MY</given-names></name><name name-style="western"><surname>Shin</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JD</given-names></name></person-group><article-title>Immunomodulatory effect of tea saponin in immune T-cells and T-lymphoma cells via regulation of Th1, Th2 immune response and MAPK/ERK2 signaling pathway</article-title><source>Immunopharmacol Immunotoxicol</source><year>2014</year><volume>36</volume><fpage>202</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.3109/08923973.2014.909849</pub-id><pub-id pub-id-type="pmid">24754510</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Bhardwaj J, Chaudhary N, Seo HJ, Kim MY, Shin TS, Kim JD. Immunomodulatory effect of tea saponin in immune T-cells and T-lymphoma cells via regulation of Th1, Th2 immune response and MAPK/ERK2 signaling pathway. Immunopharmacol Immunotoxicol. 2014;36:202&#8211;10.<pub-id pub-id-type="pmid">24754510</pub-id><pub-id pub-id-type="doi">10.3109/08923973.2014.909849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><etal/></person-group><article-title>Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice</article-title><source>J Ethnopharmacol</source><year>2020</year><volume>249</volume><fpage>112366</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2019.112366</pub-id><pub-id pub-id-type="pmid">31678415</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Yao X, Li Z, Gong X, Fu X, Xiao X, He M, et al. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice. J Ethnopharmacol. 2020;249:112366.<pub-id pub-id-type="pmid">31678415</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2019.112366</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Ni</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>B</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mechanism of Innate Immune Response Induced by Albizia julibrissin Saponin Active Fraction Using C2C12 Myoblasts</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><fpage>1576</fpage><pub-id pub-id-type="doi">10.3390/vaccines11101576</pub-id><pub-id pub-id-type="pmid">37896979</pub-id><pub-id pub-id-type="pmcid">PMC10610972</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Du J, Meng X, Ni T, Xiong B, Han Z, Zhu Y, et al. Mechanism of Innate Immune Response Induced by Albizia julibrissin Saponin Active Fraction Using C2C12 Myoblasts. Vaccines. 2023;11:1576.<pub-id pub-id-type="pmid">37896979</pub-id><pub-id pub-id-type="doi">10.3390/vaccines11101576</pub-id><pub-id pub-id-type="pmcid">PMC10610972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aslanipour</surname><given-names>B</given-names></name><name name-style="western"><surname>G&#252;lcemal</surname><given-names>D</given-names></name><name name-style="western"><surname>Nalbantsoy</surname><given-names>A</given-names></name><name name-style="western"><surname>Yusufoglu</surname><given-names>H</given-names></name><name name-style="western"><surname>Bedir</surname><given-names>E</given-names></name></person-group><article-title>Cycloartane-type glycosides from Astragalus brachycalyx FISCHER and their effects on cytokine release and hemolysis</article-title><source>Phytochem Lett</source><year>2017</year><volume>21</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.phytol.2017.05.028</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Aslanipour B, G&#252;lcemal D, Nalbantsoy A, Yusufoglu H, Bedir E. Cycloartane-type glycosides from Astragalus brachycalyx FISCHER and their effects on cytokine release and hemolysis. Phytochem Lett. 2017;21:66&#8211;73.<pub-id pub-id-type="doi">10.1016/j.phytol.2017.05.028</pub-id><pub-id pub-id-type="pmid">28827003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B</given-names></name><etal/></person-group><article-title>A single dose of Astragalus saponins adjuvanted inactivated vaccine for pseudorabies virus protected mice against lethal challenge</article-title><source>Front Vet Sci</source><year>2022</year><volume>9</volume><fpage>1036161</fpage><pub-id pub-id-type="doi">10.3389/fvets.2022.1036161</pub-id><pub-id pub-id-type="pmid">36478947</pub-id><pub-id pub-id-type="pmcid">PMC9719957</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Chang C, Wang H, Hua T, Zhang D, Hong W, Deng B, et al. A single dose of Astragalus saponins adjuvanted inactivated vaccine for pseudorabies virus protected mice against lethal challenge. Front Vet Sci. 2022;9:1036161.<pub-id pub-id-type="pmid">36478947</pub-id><pub-id pub-id-type="doi">10.3389/fvets.2022.1036161</pub-id><pub-id pub-id-type="pmcid">PMC9719957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charles</surname><given-names>NE</given-names></name></person-group><article-title>The new revolution of immunotherapy: is it time to pair it with the old one? &#8212;Yellow Leader as a candidate</article-title><source>Longhua Chin Med</source><year>2019</year><volume>2</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.21037/lcm.2019.05.01</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Charles NE. The new revolution of immunotherapy: is it time to pair it with the old one? &#8212;Yellow Leader as a candidate. Longhua Chin Med. 2019;2:7.<pub-id pub-id-type="doi">10.21037/lcm.2019.05.01</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name></person-group><article-title>Pharmacological effects of Astragaloside IV: a literature review</article-title><source>J Traditional Chin Med</source><year>2013</year><volume>33</volume><fpage>413</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/S0254-6272(13)60189-2</pub-id><pub-id pub-id-type="pmid">24024343</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Ren S, Zhang H, Mu Y, Sun M, Liu P. Pharmacological effects of Astragaloside IV: a literature review. J Traditional Chin Med. 2013;33:413&#8211;6.<pub-id pub-id-type="doi">10.1016/S0254-6272(13)60189-2</pub-id><pub-id pub-id-type="pmid">24024343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>HL</given-names></name><name name-style="western"><surname>Qin</surname><given-names>LY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lan</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Astragaloside IV improves lipid metabolism in obese mice by alleviation of leptin resistance and regulation of thermogenic network</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>30190</fpage><pub-id pub-id-type="doi">10.1038/srep30190</pub-id><pub-id pub-id-type="pmid">27444146</pub-id><pub-id pub-id-type="pmcid">PMC4957129</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Wu H, Gao Y, Shi HL, Qin LY, Huang F, Lan YY, et al. Astragaloside IV improves lipid metabolism in obese mice by alleviation of leptin resistance and regulation of thermogenic network. Sci Rep. 2016;6:30190.<pub-id pub-id-type="pmid">27444146</pub-id><pub-id pub-id-type="doi">10.1038/srep30190</pub-id><pub-id pub-id-type="pmcid">PMC4957129</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name><name name-style="western"><surname>Fang</surname><given-names>WH</given-names></name></person-group><article-title>Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>5196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.06.016</pub-id><pub-id pub-id-type="pmid">16043270</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Yang ZG, Sun HX, Fang WH. Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. Vaccine. 2005;23:5196&#8211;203.<pub-id pub-id-type="pmid">16043270</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.06.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yesilada</surname><given-names>E</given-names></name><name name-style="western"><surname>Bedir</surname><given-names>E</given-names></name><name name-style="western"><surname>Calis</surname><given-names>I</given-names></name><name name-style="western"><surname>Takaishi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohmoto</surname><given-names>Y</given-names></name></person-group><article-title>Effects of triterpene saponins from Astragalus species on in vitro cytokine release</article-title><source>J Ethnopharmacol</source><year>2005</year><volume>96</volume><fpage>71</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2004.08.036</pub-id><pub-id pub-id-type="pmid">15588652</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Yesilada E, Bedir E, Calis I, Takaishi Y, Ohmoto Y. Effects of triterpene saponins from Astragalus species on in vitro cytokine release. J Ethnopharmacol. 2005;96:71&#8211;7.<pub-id pub-id-type="pmid">15588652</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2004.08.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auyeung</surname><given-names>KK</given-names></name><name name-style="western"><surname>Han</surname><given-names>Q-B</given-names></name><name name-style="western"><surname>Ko</surname><given-names>JK</given-names></name></person-group><article-title>Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers</article-title><source>Am J Chin Med</source><year>2016</year><volume>44</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1142/S0192415X16500014</pub-id><pub-id pub-id-type="pmid">26916911</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Auyeung KK, Han Q-B, Ko JK. Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers. Am J Chin Med. 2016;44:1&#8211;22.<pub-id pub-id-type="pmid">26916911</pub-id><pub-id pub-id-type="doi">10.1142/S0192415X16500014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nico</surname><given-names>D</given-names></name><name name-style="western"><surname>Santos</surname><given-names>FN</given-names></name><name name-style="western"><surname>Borja-Cabrera</surname><given-names>GP</given-names></name><name name-style="western"><surname>Palatnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Palatnik de Sousa</surname><given-names>CB</given-names></name></person-group><article-title>Assessment of the monoterpene, glycidic and triterpene-moieties&#8217; contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>649</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.035</pub-id><pub-id pub-id-type="pmid">17014936</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Nico D, Santos FN, Borja-Cabrera GP, Palatnik M, Palatnik de Sousa CB. Assessment of the monoterpene, glycidic and triterpene-moieties&#8217; contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis. Vaccine. 2007;25:649&#8211;58.<pub-id pub-id-type="pmid">17014936</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohgitani</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>M</given-names></name></person-group><article-title>Adjuvant and Haemolytic Activities of 47 Saponins Derived from Medicinal and Food Plants</article-title><source>Biol Chem</source><year>2000</year><volume>381</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1515/BC.2000.009</pub-id><pub-id pub-id-type="pmid">10722052</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Adjuvant and Haemolytic Activities of 47 Saponins Derived from Medicinal and Food Plants. Biol Chem. 2000;381:67&#8211;74.<pub-id pub-id-type="pmid">10722052</pub-id><pub-id pub-id-type="doi">10.1515/BC.2000.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sui</surname><given-names>F</given-names></name><etal/></person-group><article-title>Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review</article-title><source>J Ethnopharmacol</source><year>2016</year><volume>188</volume><fpage>234</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2016.05.005</pub-id><pub-id pub-id-type="pmid">27154405</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Wang T, Guo R, Zhou G, Zhou X, Kou Z, Sui F, et al. Traditional uses, botany, phytochemistry, pharmacology and toxicology of Panax notoginseng (Burk.) F.H. Chen: A review. J Ethnopharmacol. 2016;188:234&#8211;58.<pub-id pub-id-type="pmid">27154405</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2016.05.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohgitani</surname><given-names>T</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>M</given-names></name></person-group><article-title>Relationship between adjuvant activity and amphipathic structure of soyasaponins</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2145</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00739-9</pub-id><pub-id pub-id-type="pmid">12706705</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. Relationship between adjuvant activity and amphipathic structure of soyasaponins. Vaccine. 2003;21:2145&#8211;51.<pub-id pub-id-type="pmid">12706705</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00739-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Ko</surname><given-names>MK</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SM</given-names></name><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Inactivated vaccine with glycyrrhizic acid adjuvant elicits potent innate and adaptive immune responses against foot-and-mouth disease</article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1289065</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2023.1289065</pub-id><pub-id pub-id-type="pmid">38029108</pub-id><pub-id pub-id-type="pmcid">PMC10644816</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Shin S, Kim HW, Ko MK, Park SH, Kim SM, Park JH, et al. Inactivated vaccine with glycyrrhizic acid adjuvant elicits potent innate and adaptive immune responses against foot-and-mouth disease. Front Microbiol. 2023;14:1289065.<pub-id pub-id-type="pmid">38029108</pub-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1289065</pub-id><pub-id pub-id-type="pmcid">PMC10644816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>HX</given-names></name><name name-style="western"><surname>Pan</surname><given-names>HJ</given-names></name></person-group><article-title>Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>1914</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.10.040</pub-id><pub-id pub-id-type="pmid">16300865</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Sun HX, Pan HJ. Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice. Vaccine. 2006;24:1914&#8211;20.<pub-id pub-id-type="pmid">16300865</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.10.040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>JH</given-names></name><name name-style="western"><surname>Iwatani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>T</given-names></name><name name-style="western"><surname>Terunuma</surname><given-names>H</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>H</given-names></name><name name-style="western"><surname>Iwakula</surname><given-names>Y</given-names></name></person-group><article-title>Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages</article-title><source>Immunology</source><year>2001</year><volume>103</volume><fpage>235</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01224.x</pub-id><pub-id pub-id-type="pmid">11412311</pub-id><pub-id pub-id-type="pmcid">PMC1783229</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Dai JH, Iwatani Y, Ishida T, Terunuma H, Kasai H, Iwakula Y. Glycyrrhizin enhances interleukin-12 production in peritoneal macrophages. Immunology. 2001;103:235&#8211;43.<pub-id pub-id-type="pmid">11412311</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01224.x</pub-id><pub-id pub-id-type="pmcid">PMC1783229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berezin</surname><given-names>VE</given-names></name><name name-style="western"><surname>Bogoyavlenskiy</surname><given-names>AP</given-names></name><name name-style="western"><surname>Turmagambetova</surname><given-names>AS</given-names></name><name name-style="western"><surname>Alexuk</surname><given-names>PG</given-names></name><name name-style="western"><surname>Zaitceva</surname><given-names>IA</given-names></name><name name-style="western"><surname>Omirtaeva</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Nanoparticles from Plant Saponins as Delivery System for Mucosal Influenza Vaccine</article-title><source>Am J Infect Dis Microbiol</source><year>2013</year><volume>1</volume><fpage>1</fpage><lpage>4</lpage></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Berezin VE, Bogoyavlenskiy AP, Turmagambetova AS, Alexuk PG, Zaitceva IA, Omirtaeva ES, et al. Nanoparticles from Plant Saponins as Delivery System for Mucosal Influenza Vaccine. Am J Infect Dis Microbiol. 2013;1:1&#8211;4.</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>WR</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>RR</given-names></name><name name-style="western"><surname>Pecanha</surname><given-names>LT</given-names></name><name name-style="western"><surname>Palatnik</surname><given-names>M</given-names></name><name name-style="western"><surname>Parente</surname><given-names>JP</given-names></name><name name-style="western"><surname>Palatnik de Sousa</surname><given-names>CB</given-names></name></person-group><article-title>Haemolytic activities of plant saponins and adjuvants. Effect of saponin on the humoral response to the FML antigen of Leishmania donovani</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>1024</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00292-7</pub-id><pub-id pub-id-type="pmid">9261952</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Santos WR, Bernardo RR, Pecanha LT, Palatnik M, Parente JP, Palatnik de Sousa CB. Haemolytic activities of plant saponins and adjuvants. Effect of saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine. 1997;15:1024&#8211;9.<pub-id pub-id-type="pmid">9261952</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00292-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kukhetpitakwong</surname><given-names>R</given-names></name><name name-style="western"><surname>Hahnvajanawong</surname><given-names>C</given-names></name><name name-style="western"><surname>Homchampa</surname><given-names>P</given-names></name><name name-style="western"><surname>Leelavatcharamas</surname><given-names>V</given-names></name><name name-style="western"><surname>Satra</surname><given-names>J</given-names></name><name name-style="western"><surname>Khunkitti</surname><given-names>W</given-names></name></person-group><article-title>Immunological adjuvant activities of saponin extracts from the pods of Acacia concinna</article-title><source>Int Immunopharmacol</source><year>2006</year><volume>6</volume><fpage>1729</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2006.08.004</pub-id><pub-id pub-id-type="pmid">16979128</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Kukhetpitakwong R, Hahnvajanawong C, Homchampa P, Leelavatcharamas V, Satra J, Khunkitti W. Immunological adjuvant activities of saponin extracts from the pods of Acacia concinna. Int Immunopharmacol. 2006;6:1729&#8211;35.<pub-id pub-id-type="pmid">16979128</pub-id><pub-id pub-id-type="doi">10.1016/j.intimp.2006.08.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagai</surname><given-names>T</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kiyohara</surname><given-names>H</given-names></name><name name-style="western"><surname>Eizaburo</surname><given-names>S</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Nagamine</surname><given-names>T</given-names></name><etal/></person-group><article-title>Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria&#8211;pertussis&#8211;tetanus vaccines</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>4824</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00215-8</pub-id><pub-id pub-id-type="pmid">11535335</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Nagai T, Suzuki Y, Kiyohara H, Eizaburo S, Kato T, Nagamine T, et al. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria&#8211;pertussis&#8211;tetanus vaccines. Vaccine. 2001;19:4824&#8211;34.<pub-id pub-id-type="pmid">11535335</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00215-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katselis</surname><given-names>GS</given-names></name><name name-style="western"><surname>Estrada</surname><given-names>A</given-names></name><name name-style="western"><surname>Gorecki</surname><given-names>DKJ</given-names></name><name name-style="western"><surname>Barl</surname><given-names>B</given-names></name></person-group><article-title>Adjuvant activities of saponins from the root of Polygala senega L</article-title><source>Can J Physiol Pharmacol</source><year>2007</year><volume>85</volume><fpage>1184</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1139/Y07-109</pub-id><pub-id pub-id-type="pmid">18066120</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Katselis GS, Estrada A, Gorecki DKJ, Barl B. Adjuvant activities of saponins from the root of Polygala senega L. Can J Physiol Pharmacol. 2007;85:1184&#8211;94.<pub-id pub-id-type="pmid">18066120</pub-id><pub-id pub-id-type="doi">10.1139/Y07-109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fleck</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kauffmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Spilki</surname><given-names>F</given-names></name><name name-style="western"><surname>Lencina</surname><given-names>CL</given-names></name><name name-style="western"><surname>Roehe</surname><given-names>PM</given-names></name><name name-style="western"><surname>Gosmanna</surname><given-names>G</given-names></name></person-group><article-title>Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>7129</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.059</pub-id><pub-id pub-id-type="pmid">16887242</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Fleck JD, Kauffmann C, Spilki F, Lencina CL, Roehe PM, Gosmanna G. Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice. Vaccine. 2006;24:7129&#8211;34.<pub-id pub-id-type="pmid">16887242</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.06.059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silveira</surname><given-names>F</given-names></name><name name-style="western"><surname>Rivera-Patron</surname><given-names>M</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>N</given-names></name><name name-style="western"><surname>Sienra</surname><given-names>S</given-names></name><name name-style="western"><surname>Checa</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1163858</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1163858</pub-id><pub-id pub-id-type="pmid">37197659</pub-id><pub-id pub-id-type="pmcid">PMC10183569</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Silveira F, Rivera-Patron M, Deshpande N, Sienra S, Checa J, Moreno M, et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice. Front Immunol. 2023;14:1163858.<pub-id pub-id-type="pmid">37197659</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1163858</pub-id><pub-id pub-id-type="pmcid">PMC10183569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cibulski</surname><given-names>SP</given-names></name><name name-style="western"><surname>Mourglia-Ettlin</surname><given-names>G</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>TF</given-names></name><name name-style="western"><surname>Quirici</surname><given-names>L</given-names></name><name name-style="western"><surname>Roehe</surname><given-names>PM</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F</given-names></name><etal/></person-group><article-title>Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>1162</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.029</pub-id><pub-id pub-id-type="pmid">26826546</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Cibulski SP, Mourglia-Ettlin G, Teixeira TF, Quirici L, Roehe PM, Ferreira F, et al. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake. Vaccine. 2016;34:1162&#8211;71.<pub-id pub-id-type="pmid">26826546</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Exploration of the immuno-adjuvant effect and mechanism of Anemoside B4 through network pharmacology and experiment verification</article-title><source>Phytomedicine</source><year>2024</year><volume>124</volume><fpage>155302</fpage><pub-id pub-id-type="doi">10.1016/j.phymed.2023.155302</pub-id><pub-id pub-id-type="pmid">38176273</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Shen L, Luo H, Fan L, Su Z, Yu S, Cao S, et al. Exploration of the immuno-adjuvant effect and mechanism of Anemoside B4 through network pharmacology and experiment verification. Phytomedicine. 2024;124:155302.<pub-id pub-id-type="pmid">38176273</pub-id><pub-id pub-id-type="doi">10.1016/j.phymed.2023.155302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name></person-group><article-title>Adjuvant effect of saponins isolated from the sepal of Physalis alkekengi L. var. francheti (Mast.) Makino fruit on the immune responses to ovalbumin in mice. Afr</article-title><source>J Immunol Res</source><year>2017</year><volume>5</volume><fpage>425</fpage><lpage>31</lpage></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Liu Y, Han S, Zhu Y, Li Y, Zhu X, Wang G. Adjuvant effect of saponins isolated from the sepal of Physalis alkekengi L. var. francheti (Mast.) Makino fruit on the immune responses to ovalbumin in mice. Afr. J Immunol Res. 2017;5:425&#8211;31.</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>